

Appendix 1. Bibliography

Articles Accepted for Efficacy Analysis

1. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. *Int J Obes Relat Metab Disord*. 1992;16:(4)269-77. [Rec#: 7]
2. Astrup A, Breum L, Toubro S, Hein P, Quaade F. Ephedrine and weight loss. *Int J Obes Relat Metab Disord*. 1992;16:(9)715. [Rec#: 8]
3. Astrup A, Buemann B, Christensen NJ, Toubro S, Thorbek G, Victor OJ, et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. *Metabolism*. 1992;41:(7)686-8. [Rec#: 9]
4. Astrup A, Toubro S, Cannon S, Hein P, Madsen J. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. *Metabolism*. 1991;40:(3)323-9. [Rec#: 13]
5. Belfie L, Petrie H, Chown S, Duncan AM, Gawron SJ, Conquer J, et al. Safety and effectiveness of an herbal dietary supplement containing ephedra (ma huang) and caffeine (guarana extract) when used in combination with a supervised diet and exercise intervention. *Obesity Research Program Abstracts*. 2001;9:(Suppl 3)26. [Rec#: 317]
6. Bell DG, Jacobs I. Combined caffeine and ephedrine ingestion improves run times of Canadian Forces Warrior Test. *Aviat Space Environ Med*. 1999;70:(4)325-9. [Rec#: 24]
7. Bell DG, Jacobs I, Ellerington K. Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. *Med Sci Sports Exercise*. 2001;33:1399-1403. [Rec#: 512]
8. Bell DG, Jacobs I, McLellan TM, Miyazaki M, Sabiston CM. Thermal regulation in the heat during exercise after caffeine and ephedrine ingestion. *Aviat Space Environ Med*. 1999;70:(6)583-8. [Rec#: 25]
9. Bell DG, Jacobs I, McLellan TM, Zamecnik J. Reducing the dose of combined caffeine and ephedrine preserves the ergogenic effect. *Aviat Space Environ Med*. 2000;71:(4)415-9. [Rec#: 26]
10. Bell DG, Jacobs I, Zamecnik J. Effects of caffeine, ephedrine and their combination on time to exhaustion during high-intensity exercise. *Eur J Appl Physiol Occup Physiol*. 1998;77:(5)427-33. [Rec#: 27]
11. Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. *International Journal of Obesity*. (In Press). [Rec#: 474]
12. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. *Int J Obes Relat Metab Disord*. 2001;25:(3)316-24. [Rec#: 333]
13. Breum L, Pedersen JK, Ahlstrom F, Frimodt-Moller J. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. *Int J Obes Relat Metab Disord*. 1994;18:(2)99-103. [Rec#: 41]

Articles Accepted for Efficacy Analysis (continued)

14. Buemann B, Marckmann P, Christensen NJ, Astrup A. The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet. *Int J Obes Relat Metab Disord*. 1994;18:(5)329-32. [Rec#: 45]
15. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. *Int J Obes Relat Metab Disord*. 1993;17:(Suppl 1)S73-8. [Rec#: 68]
16. de Jonge L, Frisard M, Blanchard D, Greenway F. Safety and efficacy of an herbal dietary supplement containing caffeine and ephedra for obesity treatment. *Obesity Research Program Abstracts*. 2001;9:(Suppl 3)20. [Rec#: 316]
17. Donikyan LA. A double-blind randomized, placebo-controlled, multicenter clinical study to evaluate the safety and efficacy of a natural herbal formulation when taken as recommended for weight control. Boca Raton, FL: Rexall Sundown. 2002. [Rec#: 509]
18. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: human studies. *Int J Obes*. 1986;10:(6)467-81. [Rec#: 83]
19. Geissler CA. Effects of weight loss, ephedrine and aspirin on energy expenditure in obese women. *Int J Obes Relat Metab Disord*. 1993;17(Suppl 1):S45-8. [Rec#: 97]
20. Greenway F, deJonge L, Blanchard D, et al. *Evaluation of a dietary herbal supplement containing caffeine and ephedrine on metabolic rate, body composition, serum lipids and tolerability*. (Unpublished). [Rec#: 475]
21. Greenway FL, Raum WJ, DeLany JP. The effect of an herbal dietary supplement containing ephedrine and caffeine on oxygen consumption in humans. *J Altern Complement Med*. 2000;6:(6)553-5. [Rec#: 106]
22. Horton TJ, Geissler CA. Aspirin potentiates the effect of ephedrine on the thermogenic response to a meal in obese but not lean women. *Int J Obes*. 1991;15:(5)359-66. [Rec#: 123]
23. Horton TJ, Geissler CA. Post-prandial thermogenesis with ephedrine, caffeine and aspirin in lean, pre-disposed obese and obese women. *Int J Obes Relat Metab Disord*. 1996;20:(2)91-7. [Rec#: 124]
24. Ingerslev J, Svendsen TL, Mork A. Is an ephedrine caffeine treatment contraindicated in hypertension? *Int J Obesity Related Metabol Disord*. 1997;21:(8)666-673. [Rec#: 132]
25. Jaedig S, Henningsen NC. Increased metabolic rate in obese women after ingestion of potassium, magnesium- and phosphate-enriched orange juice or injection of ephedrine. *Int J Obes*. 1991;15:(6)429-36. [Rec#: 391]
26. Jensen KB, Dano P, Draeby N, Hansen SH, Kanstrup J. [Elsinore tablets and ephedrine as slimming agents]. *Ugeskr Laeger*. 1980;142:(23)1499-501. [Rec#: 536]
27. Jonderko K, Kucio C. Effect of anti-obesity drugs promoting energy expenditure, yohimbine and ephedrine, on gastric emptying in obese patients. *Aliment Pharmacol Ther*. 1991;5:(4)413-8. [Rec#: 137]
28. Kaats GR, Aldeman JA. Effects of multiple herbal formulation on body composition, blood chemistry, vital signs and self-reported energy levels and appetite control. *Int J Obesity Related Metabol Disord*. 1994;18:(Suppl 2)145(Abtract). [Rec#: 139]
29. Kalman D, Incledon T, Gaunaud I, et al. An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra/caffeine weight loss product in healthy overweight adults. *International Journal of Obesity*. (In Press). [Rec#: 476]

Articles Accepted for Efficacy Analysis (continued)

30. Kalman DS, Colker CM, Shi Q, Swain MA. Effects of a weight-loss aid in healthy overweight adults: Double-blind, placebo-controlled clinical trial. *Curr Therapeut Res*. 2000;61:(4)199-205. [Rec#: 140]
31. Kettle R, Toubro S, Astrup A. Ephedrine, caffeine enhances abdominal fat loss in females. *Int J Obesity Related Metabol Disord*. 1998;22(Suppl 3):S264(Abstract). [Rec#: 510]
32. Krieger DR, Daly PA, Dulloo AG, Ransil BJ, Young JB, Landsberg L. Ephedrine, caffeine and aspirin promote weight loss in obese subjects. *Trans Assoc Am Physicians*. 1990;103:307-12. [Rec#: 151]
33. Liu YL, Toubro S, Astrup A, Stock MJ. Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. *Int J Obes Relat Metab Disord*. 1995;19:(9)678-85. [Rec#: 169]
34. Lumholtz IB, Thorsteinsson B, Wamberg T, Lehnshau A, Hansen G, Spellerberg S, et al. [Ephedrine in the treatment of obesity. A double-blind cross-over trial of the effect of Elsinore tablets]. *Ugeskr Laeger*. 1980;142:(23)1487-90. [Rec#: 173]
35. Malchow-Moller A, Larsen S, Hey H, Stokholm KH, Juhl E, Quaade F. Ephedrine as an anorectic: the story of the 'Elsinore pill.' *Int J Obes*. 1981;5:(2)183-7. [Rec#: 177]
36. Martinet A, Hostettmann K, Schutz Y. Thermogenic effects of commercially available plant preparations aimed at treating human obesity. *Phytomedicine*. 1999;6:(4)231-8. [Rec#: 335]
37. Moheb MA, Geissler CA, Lancer K. Effect of ephedrine, caffeine, and aspirin, in combinations of weight loss in obese women. *Int J Obesity Related Metabol Disord*. 1998;22:(Suppl 3)S264(Abstract). [Rec#: 193]
38. Molnar D. Effects of ephedrine and aminophylline on resting energy expenditure in obese adolescents. *Int J Obes Relat Metab Disord*. 1993;17:(Suppl 1)S49-52. [Rec#: 194]
39. Molnar D, Torok K, Erhardt E, Jeges S. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. *Int J Obes Relat Metab Disord*. 2000;24:(12)1573-8. [Rec#: 195]
40. Morgan JB, York DA, Wasilewska A, Portman J. A study of the thermic responses to a meal and to a sympathomimetic drug (ephedrine) in relation to energy balance in man. *Br J Nutr*. 1982;47:(1)21-32. [Rec#: 197]
41. Nasser JA, Wang V, Chen GC, Solomon JL, Heymsfield SB, Boozer CN. Efficacy trial for weight loss of an herbal supplement of Ma huang and guarana. *FASEB J*. 1999;13:(5,Prt.2)A874(Abstract). [Rec#: 204]
42. Norregaard J, Jorgensen S, Mikkelsen KL, Tonnesen P, Iversen E, Sorensen T, et al. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. *Clin Pharmacol Ther*. 1996;60:(6)679-86. [Rec#: 210]
43. Oksbjerg N, Meyer T, Hvid-Jacobsen K. [Aerobic training increases the effect of ephedrine on energy expenditure]. *Ugeskr Laeger*. 1986;148:(32)2021-4. [Rec#: 214]
44. Pasquali R, Baraldi G, Cesari MP, Melchionda N, Zamboni M, Stefanini C, et al. A controlled trial using ephedrine in the treatment of obesity. *Int J Obes*. 1985;9:(2)93-8. [Rec#: 220]
45. Pasquali R, Casimirri F, Melchionda N, Grossi G, Bortoluzzi L, Morselli Labate AM, et al. Effects of chronic administration of ephedrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects. *Clin Sci (Colch)*. 1992;82:(1)85-92. [Rec#: 222]

Articles Accepted for Efficacy Analysis (continued)

46. Pasquali R, Cesari MP, Melchionda N, Stefanini C, Raitano A, Labo G. Does ephedrine promote weight loss in low-energy-adapted obese women? *Int J Obes*. 1987;11:(2)163-8. [Rec#: 223]
47. Pasternak H, Jacobs I, Bell D. Effects of ingesting caffeine and ephedrine on muscular endurance. *Can J Appl Physiol*. 1999;24:(5)471. [Rec#: 511]
48. Quaaade F, Astrup A, Breum L, Toubro S, Hein P. [The effect of an ephedrine/caffeine combination as a supplement to a weight-reducing diet. A randomized, placebo-controlled, double-blind trial]. *Ugeskr Laeger*. 1992;154:(18)1258-63. [Rec#: 230]
49. Roed P, Hansen PW, Bidstrup B, Kaern M, Helles A, Petersen KP. [Elsinore banting tablets. A controlled clinical trial in general practice]. *Ugeskr Laeger*. 1980;142:(23)1491-5. [Rec#: 535]
50. Shannon JR, Gottesdiener K, Jordan J, Chen K, Flattery S, Larson PJ, et al. Acute effect of ephedrine on 24-h energy balance. *Clin Sci (Colch)*. 1999;96:(5)483-91. [Rec#: 243]
51. Shugarman AE. Effect of thermogenic dietary supplements on resting metabolic rate in healthy male and female volunteers. Utah: University of Utah. 1998. [Rec#: 305]
52. Sidney KH, Lefcoe NM. The effects of ephedrine on the physiological and psychological responses to submaximal and maximal exercise in man. *Med Sci Sports*. 1977;9:(2)95-9. [Rec#: 247]
53. Toubro S, Astrup A. Randomised comparison of diets for maintaining obese subjects' weight after major weight loss: ad lib, low fat, high carbohydrate diet v fixed energy intake. *BMJ*. 1997;314:(7073)29-34. [Rec#: 261]
54. Toubro S, Astrup A V, Breum L, Quaaade F. Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture. *Int J Obes Relat Metab Disord*. 1993;17: (Suppl 1)S69-72. [Rec#: 263]
55. Van Mil E, Molnar D. Drug treatment in obese adolescents. *Int J Obesity*. 2000. 24:(Suppl 1)S184(Abstract). [Rec#: 272]
56. Waluga M, Janusz M, Karpel E, Hartleb M, Nowak A. Cardiovascular effects of ephedrine, caffeine and yohimbine measured by thoracic electrical bioimpedance in obese women. *Clin Physiol*. 1998;18:(1)69-76. [Rec#: 276]

Articles Rejected from Efficacy Analysis

1. Abdallah AH, Tye A, Lapidus JB, Patil P. Effects of ephedrine isomers on myocardial catecholamines. *Life Sci.* 1967;6:(1)39-43. [Rec#: 420]
2. Abernethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. *Br J Clin Pharmacol.* 1985;20:(1)61-6. [Rec#: 378]
3. Acheson KJ, Zahorska-Markiewicz B, Pittet P, Anantharaman K, Jequier E. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. *Am J Clin Nutr.* 1980;33:(5)989-97. [Rec#: 371]
4. Ahrendt DM. Ergogenic aids: counseling the athlete. *American Family Physician.* 2001;63:(5)913-922. [Rec#: 303]
5. al-Khalil S, Alkofahi A, el-Eisawi D, al-Shibib A. Transthorine, a new quinoline alkaloid from *Ephedra transitoria*. *J Nat Prod.* 1998;61:(2)262-3. [Rec#: 442]
6. Altschuler S, Conte A, Sebok M, Marlin RL, Winick C. Three controlled trials of weight loss with phenylpropanolamine. *Int J Obes.* 1982;6:(6)549-56. [Rec#: 399]
7. Anastasio GD, Harston P. Fetal tachycardia associated with maternal use of pseudoephedrine, an OTC oral decongestant. *J Am Board Fam Pract.* 1992;5:(5)527-528. [Rec#: 3]
8. Anon. Herbs to handle with care. New York: Newsweek. 1996.
9. Anselme F, Collomp K, Mercier B, Ahmaidi S, Prefaut C. Caffeine increases maximal anaerobic power and blood lactate concentration. *Eur J Appl Physiol Occup Physiol.* 1992;65:(2)188-91. [Rec#: 541]
10. Assimos DG, Langenstroer P, Leinbach RF, Mandel NS, Stern JM, Holmes RP. Guaifenesin - and ephedrine-induced stones. *J Endourol.* 1999;13:(9)665-7. [Rec#: 4]
11. Astrup A. *Commentary on safety of products containing ephedrine alkaloids/caffeine.* (Unpublished). [Rec#: 477]
12. Astrup A. Thermogenesis in human brown adipose tissue and skeletal muscle induced by sympathomimetic stimulation. *Acta Endocrinol Suppl (Copenh).* 1986;278:1-32. [Rec#: 389]
13. Astrup A. Thermogenic drugs as a strategy for treatment of obesity. *Endocrine.* 2000;13:(2)207-12. [Rec#: 5]
14. Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. *Obes Res.* 1995;3:(Suppl 4)537S-540S. [Rec#: 6]
15. Astrup A, Lundsgaard C. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. *Exp Clin Endocrinol Diabetes.* 1998;106:(Suppl 2)29-34. [Rec#: 10]
16. Astrup A, Lundsgaard C, Madsen J, Christensen N J. Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. *Am J Clin Nutr.* 1985;42:(1)83-94. [Rec#: 11]
17. Astrup A, Madsen J, Holst JJ, Christensen NJ. The effect of chronic ephedrine treatment on substrate utilization, the sympathoadrenal activity, and energy expenditure during glucose-induced thermogenesis in man. *Metabolism.* 1986;35:(3)260-5. [Rec#: 387]
18. Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. *Int J Obes Relat Metab Disord.* 1993;17:(Suppl 1)S41-3. [Rec#: 12]

Articles Excluded from Efficacy Analysis (continued)

19. Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. *Am J Clin Nutr*. 1990;51:(5)759-67. [Rec#: 499]
20. Astrup A, Toubro S, Christensen NJ, Quaade F. Pharmacology of thermogenic drugs. *Am J Clin Nutr*. 1992;55:(1 Suppl)246S-248S. [Rec#: 397]
21. Astrup AV. Treatment of obesity with thermogenic agents. *Nutrition*. 1989;5:(1)70. [Rec#: 403]
22. Aswal BS, Bhakuni DS, Goel AK, Kar K, Mehrotra BN. Screening of Indian plants for biological activity - Part XI. *Indian J Exp Biol*. 1984;22:(9)487-504. [Rec#: 14]
23. Atkinson RL. The herbal ephedra and caffeine debate continues. *International Journal of Obesity*. 2002;26:589. [Rec#: 531]
24. Atkinson RL, Blank RC, Loper JF, Schumacher D, Lutes RA. Combined drug treatment of obesity. *Obes Res*. 1995;3:(Suppl 4)497S-500S. [Rec#: 15]
25. Audicana M, Urrutia I, Echechipia S, Munoz D, Fernandez de Corres L. Sensitization to ephedrine in oral antitarrhal drugs. *Contact Dermatitis*. 1991;24:(3)223. [Rec#: 366]
26. Aviado DM, Wnuck AL, De Beer EJ. Cardiovascular effects of sympathomimetic bronchodilators: epinephrine, ephedrine, pseudoephedrine, isoproterenol, mehtoxyphenamine and isoprophenamine. *J Pharmacology and Experimental Therapeutics*. 1958;122:(407-417). [Rec#: 405]
27. Axelrod J. Studies on sympathomimetic amines: I. The biotransformation and physiological disposition of 1-ephedrine and 1-norephedrine. *J Pharmacol Exper Therapeut*. 1953;109:(1)62-73. [Rec#: 16]
28. Backer R, Tautman D, Lowry S, Harvey C M, Poklis A. Fatal ephedrine intoxication. *J Forensic Sci*. 1997;42:(1)157-9. [Rec#: 17]
29. Badiei B, Faciane J, Sly RM. Effect of theophylline, ephedrine and their combination upon exercise-induced airway obstruction. *Ann Allergy*. 1975;35:(1)32-6. [Rec#: 18]
30. Bailey CJ, Thornburn CC, Flatt PR. Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. *Gen Pharmacol*. 1986;17:(2)243-6. [Rec#: 388]
31. Bale JF Jr., Fountain MT, Shaddy R. Phenylpropanolamine-associated CNS complications in children and adolescents. *Am J Dis Child*. 1984;138:(7)683-5. [Rec#: 19]
32. Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. *Br J Clin Pharmacol*. 1998;45:(5)496-500. [Rec#: 439]
33. Baselt RC. Disposition of toxic drugs and chemicals in man. Davis, CA: Biomedical Publications. 1982. pp. 108-111. [Rec#: 433]
34. Baselt RC. Ephedra. In: Baselt RC. (Ed) *Disposition of Toxic Drugs and Chemicals in Man* (2nd). Foster City, CA: Chemical Toxicology Institute. 1982a. [Rec#: 21]
35. Baselt RC. Caffeine. In: Baselt RC. (Ed) *Drugs and Chemicals in Man* (2nd). Foster City, CA: Chemical Toxicology Institute. 1982b. pp. 108-111. [Rec#: 20]
36. Battig K. Acute and chronic cardiovascular and behavioural effects of caffeine, aspirin and ephedrine. *Int J Obes Relat Metab Disord*. 1993;17:(Suppl 1)S61-4. [Rec#: 22]

Articles Excluded from Efficacy Analysis (continued)

37. Beck RA, Mercado DL, Seguin SM, Andrade WP, Cushner HM. Cardiovascular effects of pseudoephedrine in medically controlled hypertensive patients. *Arch Intern Med.* 1992;152:(6)1242-5. [Rec#: 23]
38. Bell DG, Jacobs I, Ellerington K. Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. *Med Sci Sports Exerc.* 2001;33:(8)1399-403. [Rec#: 481]
39. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. *J Clin Epidemiol* 1993 46:(11)1331-6. [Rec#: 325]
40. Betz JM, Gay ML, Mossoba MM, Adams S, Portz BS. Chiral gas chromatographic determination of ephedrine-type alkaloids in dietary supplements containing Ma Huang. *J AOAC Int.* 1997;80:(2)303-15. [Rec#: 28]
41. Bierman CW, Pierson WE, Shapiro GG. Exercise-induced asthma. Pharmacological assessment of single drugs and drug combinations. *JAMA.* 1975;234:(3)295-8. [Rec#: 29]
42. Blanc PD, Kuschner WG, Katz PP, Smith S, Yelin EH. Use of herbal products, coffee or black tea, and over-the-counter medications as self-treatments among adults with asthma. *J Allergy Clin Immunol.* 1997;100:(6 Pt 1)789-91. [Rec#: 30]
43. Blanc S, Leuenberger P, Berger JP, et al. Judgments of trained observers on adverse drug reactions. *Clinical Pharmacology and Therapeutics.* 1979;25:(5)493-498. [Rec#: 461]
44. Blaszyk HJ, Edwards WD. Sudden cardiac death in a healthy 28-year-old male truck driver abusing ephedrine. *J Forensic Sci.* 1997;42:(1)169-. [Rec#: 348]
45. Blau JJ. Ephedrine nephrolithiasis associated with chronic ephedrine abuse. *J Urol.* 1998;160:(3 Pt 1)825. [Rec#: 31]
46. Blenkinsopp A, Bradley C. Patients, society, and the increase in self medication. *BMJ.* 1996;312:(7031)629-32. [Rec#: 533]
47. Blumenthal M. FDA Holds Expert Advisory Committee Hearing on Ma Huang: Experts Recommend Appropriate Labeling and Warnings - Not Banning the Herb. *HERBALGRAM.* 1996;36:21-3, 73. [Rec#: 32]
48. Blumenthal M, Busse WR. Ephedra. In: Blumenthal M, Busse WR. (Eds) (Translated by) Klein S, Rister RS. Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications; 1998. p. 125-6, 414-6, 475-6. [Rec#: 33]
49. Bondi M, Grugni G, Velardo A, Biella O, Venneri MG, Morabito F, et al. Adrenomedullary response to caffeine in prepubertal and pubertal obese subjects. *Int J Obes Relat Metab Disord.* 1999;23:(9)992-6. [Rec#: 376]
50. Boozer CN, Daly PA, Blanchard D, Nasser JA, Solomon JL, Homel P. Herbal ephedra/caffeine for weight loss: A 6-month safety and efficacy trial. 2000. (Abstract). [Rec#: 34]
51. Borum M. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. *American Journal of Gastroenterology.* 2001;94:2430-4. [Rec#: 521]
52. Boston LN. Dysuria following ephedrine therapy. *Med Times.* 1928;56:94-95. [Rec#: 35]
53. Boston LN. Dysuria following ephedrine therapy. *The Medical Times.* 1928;56:(Apr)94-95. [Rec#: 302]
54. Boullata JI, Nace AM. Safety issues with herbal medicine. *Pharmacotherapy.* 2000;20:(3)257-69. [Rec#: 36]

Articles Excluded from Efficacy Analysis (continued)

55. Bowyer JF, Newport GD, Slikker W Jr., Gough B, Ferguson SA, Tor-Agbidye J. An evaluation of l-ephedrine neurotoxicity with respect to hyperthermia and caudate/putamen microdialysate levels of ephedrine, dopamine, serotonin, and glutamate. *Toxicol Sci.* 2000;55:(1)133-42. [Rec#: 37]
56. Bracco D, Ferrarra JM, Arnaud MJ, Jequier E, Schutz Y. Effects of caffeine on energy metabolism, heart rate, and methylxanthine metabolism in lean and obese women. *Am J Physiol.* 1995;269:(4 Pt 1)E671-8. [Rec#: 375]
57. Bradley JG. Nonprescription drugs and hypertension. Which ones affect blood pressure? *Postgrad Med.* 1991;89:(6)195-7, 201-2. [Rec#: 38]
58. Bradley JG, Kallail KJ, Dorsch JN, Fox J. The effects of pseudoephedrine on blood pressure in patients with controlled, uncomplicated hypertension: a randomized, double-blind, placebo-controlled trial. *J Am Board Fam Pract.* 1991;4:(4)201-6. [Rec#: 39]
59. Brater DC, Kaojarern S, Benet LZ, Lin ET, Lockwood T, Morris RC, et al. Renal excretion of pseudoephedrine. *Clin Pharmacol Ther.* 1980;28:(5)690-4. [Rec#: 443]
60. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. *Ann Intern Med.* 1993;119:(7 Pt 2)707-13. [Rec#: 306]
61. Bray GA. Drug treatment of obesity. *Baillieres Best Pract Res Clin Endocrinol Metab.* 1999;13:(1)131-48. [Rec#: 40]
62. Bright TP, Sandage BW Jr., Fletcher HP. Selected cardiac and metabolic responses to pseudoephedrine with exercise. *J Clin Pharmacol.* 1981;21:(11-12 Pt 1)488-92. [Rec#: 416]
63. Britton MG, Empey DW, John GC, McDonnell KA, Hughes DT. Histamine challenge and anterior nasal rhinometry: their use in the assessment of pseudoephedrine and triprolidine as nasal decongestants in subjects with hayfever. *Br J Clin Pharmacol.* 1978;6:(1)51-8. [Rec#: 419]
64. Brown NJ, Ryder D, Branch RA. A pharmacodynamic interaction between caffeine and phenylpropanolamine. *Clin Pharmacol Ther.* 1991;50:(4)363-71. [Rec#: 42]
65. Bruneton J. Phenethylamines. In: Bruneton J. *Pharmacognosy, Phytochemistry, Medicinal Plants.* Paris, France, Secausuc, NY: Lavoisier Pub; 1996. pp. 711-15. [Rec#: 43]
66. Bruno A, Nolte KB, Chapin J. Stroke associated with ephedrine use. *Neurology.* 1993;43:(7)1313-6. [Rec#: 44]
67. Bucci LR. Selected herbals and human exercise performance. *Am J Clin Nutr.* 2000;72:(2 Suppl)624S-36S. [Rec#: 479]
68. Bukowiecki L, Jahjah L, Follea N. Ephedrine, a potential slimming drug, directly stimulates thermogenesis in brown adipocytes via beta-adrenoreceptors. *Int J Obes.* 1982;6:(4)343-50. [Rec#: 367]
69. Burkhardt KK. Intravenous propranolol reverses hypertension after sympathomimetic overdose: two case reports. *J Toxicol Clin Toxicol.* 1992;30:(1)109-14. [Rec#: 46]
70. Bye C, Dewsbury D, Peck AW. Effects on the human central nervous system of the two isomers of ephedrine and triprolidine and their interaction. *Br J Clin Pharmacol.* 1974;1:(1)71-78. [Rec#: 47]

Articles Excluded from Efficacy Analysis (continued)

71. Bye C, Hill HM, Hughes DT, Peck AW. A comparison of plasma levels of L(+) pseudoephedrine following different formulations, and their relation to cardiovascular and subjective effects in man. *Eur J Clin Pharmacol*. 1975;8:(1)47-53. [Rec#: 415]
72. Capwell RR. Ephedrine-induced mania from an herbal diet supplement. *Am J Psychiatry*. 1995;152:(4)647. [Rec#: 48]
73. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Caffeine pharmacokinetics in obesity and following significant weight reduction. *Int J Obes Relat Metab Disord*. 1995;19:(4)234-9. [Rec#: 380]
74. Case B, Oszko MA. Use of an algorithm to evaluate published reports of adverse drug reactions. *Am J Hosp Pharm*. 1991;48:(1)121-2. [Rec#: 331]
75. Catlin DH, Hatton CK. Use and abuse of anabolic and other drugs for athletic enhancement. *Adv Intern Med*. 1991;36:399-424. [Rec#: 49]
76. CDC. Adverse events associated with ephedrine containing products. *MMWR*. 1995;45:689-93. [Rec#: 434]
77. CDC. Adverse events associated with ephedrine-containing products. *JAMA*. 1996;276:(21)1711-2. [Rec#: 436]
78. Cetaruk E W, Aaron C K. Hazards of nonprescription medications. *Emerg Med Clin North Am*. 1994;12:(2)483-510. [Rec#: 50]
79. Chait L. Factors influencing the reinforcing and subjective effects of ephedrine in humans. *Psychopharmacology*. 1994;113:381-7. [Rec#: 520]
80. Chance MRA. Aggregation as a factor influencing the toxicity of sympathomimetic amines in mice. *J Pharmacol Exper Therapeut*. 1946;87:214-19. [Rec#: 51]
81. Chappel CI, Rona G, Balazs T, Gaudry R. Comparison of cardiotoxic actions of certain sympathomimetic amines. *Cdn J Biochem Physiol*. 1959;37:35-42. [Rec#: 52]
82. Chen KK. The effect of ephedrine on experimental shock and hemorrhage. *Proceedings of the Society for Experimental Biology and Medicine*. 1925;22:(3)203-206. [Rec#: 406]
83. Chen KK. The effect of repeated administration of ephedrine. *Proc Soc Exper Biol Med*. 1925;22:(8)568-570. [Rec#: 54]
84. Chen KK. The acute toxicity of ephedrine. *Proc Soc Exper Biol Med*. 1925a;22:(7)404-405. [Rec#: 53]
85. Chen KK. A comparative study of ephedrine, pseudoephedrine and beta-phenyl-ethylamine. *Archives of Internal Medicine*. 1927;39:404-411. [Rec#: 407]
86. Chen KK. A comparative study of synthetic and natural ephedrines. *J Pharmacol Exper Therapeutics*. 1928;33:237-258. [Rec#: 408]
87. Chen KK, Kao CH. Ephedrine and pseudoephedrine, their isolation, constitution, isomerism, properties, derivatives and synthesis. *J Am Pharmaceut Assoc*. 1926;15:(8)625-639. [Rec#: 409]
88. Chen KK, Meek WJ. A comparative study of ephedrine, tyramine and epinephrine with special reference to the circulation. *J Pharmacol Exper Therapeut*. 1926;28:59-76. [Rec#: 411]
89. Chen KK, Meek WJ. Further studies on the effect of ephedrine on the circulation. *J Am Pharmaceut Assoc*. 1926;28:31-57. [Rec#: 410]
90. Chen KK, Poth EJ. The racial difference of the mydriatic action of ephedrines, cocaine, and euphthalmine. *Proc Soc Exper Biol Med*. 1927;25:(2)150-151. [Rec#: 413]

Articles Excluded from Efficacy Analysis (continued)

91. Chen KK, Schmidt CF. The action of ephedrine, the active principle of the Chinese drug Ma Hung. *J Pharmacol Exper Therapeut.* 1924;24:339-357. [Rec#: 414]
92. Chen KK, Schmidt CF. Ephedrine and related substances. *Medicine.* 1930;9:1-117. [Rec#: 55]
93. Chen KK, Wu C-K, Henriksen E. Ephedrine homologs and isomers: Relationship between their pharmacological action and their chemical constitution and stereoisomerism. *Proc Soc Exper Biol Med.* 1929;26:(4)348. [Rec#: 56]
94. Chen KK, Wu C-K, Henriksen E. Relationship between the pharmacological action and the chemical constitution and configuration of the optical isomers of ephedrine and related compounds. *J Pharmacol Exper Therapeut.* 1929;36:363-400. [Rec#: 57]
95. Chestnut DH, Weiner CP, Wang JP, Herrig JE, Martin JG. The effect of ephedrine upon uterine artery blood flow velocity in the pregnant guinea pig subjected to terbutaline infusion and acute hemorrhage. *Anesthesiology.* 1987;66:(4)508-12. [Rec#: 370]
96. Chicharro M, Zapardiel A, Bermejo E, Perez JA, Hernandez L. Direct determination of ephedrine and norephedrine in human urine by capillary zone electrophoresis. *J Chromatogr.* 1993;622:(1)103-8. [Rec#: 444]
97. Chua SS, Benrimoj SI. Non-prescription sympathomimetic agents and hypertension. *Med Toxicol Adverse Drug Exp.* 1988;3:(5)387-417. [Rec#: 58]
98. Chua SS, Benrimoj SI, Gordon RD, Williams G. A controlled clinical trial on the cardiovascular effects of single doses of pseudoephedrine in hypertensive patients. *Br J Clin Pharmacol.* 1989;28:(3)369-72. [Rec#: 59]
99. Clarkson PM, Thompson HS. Drugs and sport. Research findings and limitations. *Sports Med.* 1997;24:(6)366-84. [Rec#: 60]
100. Clemons JM, Crosby SL. Cardiopulmonary and subjective effects of a 60 mg dose of pseudoephedrine on graded treadmill exercise. *J Sports Med Phys Fitness.* 1993;33:(4)405-12. [Rec#: 61]
101. Clovis WL. Mania and cough syrup. *J Clin Psychiatry.* 1993;54:(5)200. [Rec#: 62]
102. Coates ML, Rembold CM, Farr BM. Does pseudoephedrine increase blood pressure in patients with controlled hypertension? *J Fam Pract.* 1995;40:(1)22-6. [Rec#: 63]
103. Cockings JG, Brown M. Ephedrine abuse causing acute myocardial infarction. *Med J Aust.* 1997;167:(4)199-200. [Rec#: 64]
104. Colditz GA. Economic costs of obesity. *Am J Clin Nutr.* 1992;55:(2 Suppl)503S-507S. [Rec#: 543]
105. Costello JF, May CS, Paterson JW, Pickup ME. Pharmacokinetics of ephedrine in asthmatics receiving acute and chronic treatment. *Br J Clin Pharmacol.* 1975;2:(2)180-181. [Rec#: 65]
106. Cowley G. Herbal warning. *New York: Newsweek.* 1996.
107. Cupp MJ. Herbal remedies: adverse effects and drug interactions. *Am Fam Physician.* 1999;59:(5)1239-45. [Rec#: 66]
108. Dalton R. Mixed bipolar disorder precipitated by pseudoephedrine hydrochloride. *South Med J.* 1990;83:(1)64-5. [Rec#: 67]
109. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. *J Clin Epidemiol.* 1993;46:(11)1323-30. [Rec#: 328]

Articles Excluded from Efficacy Analysis (continued)

110. Dangoumau J, Evreux JC, Jouglard J. [Method for determination of undesirable effects of drugs]. *Therapie*. 1978;33:(3)373-81. [Rec#: 323]
111. Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. *J Accid Emerg Med*. 1995;12:(1)49-51. [Rec#: 69]
112. Derreza H, Fine MD, Sadaniantz A. Acute myocardial infarction after use of pseudoephedrine for sinus congestion. *J Am Board Fam Pract*. 1997;10:(6)436-8. [Rec#: 70]
113. Dewsnap P, Libby G. A case of affective psychosis after routine use of proprietary cold remedy containing phenylpropanolamine. *Hum Exp Toxicol*. 1992;11:(4)295-6. [Rec#: 71]
114. Diaz JL. Ethnopharmacology of sacred psychoactive plants used by the Indians of Mexico. *Annu Rev Pharmacol Toxicol*. 1977;17:647-75. [Rec#: 72]
115. Dickerson J, Perrier D, Mayersohn M, Bressler R. Dose tolerance and pharmacokinetic studies of L (+) pseudoephedrine capsules in man. *Eur J Clin Pharmacol*. 1978;14:(4)253-9. [Rec#: 73]
116. Dingemanse J, Guentert T, Gieschke R, Stabl M. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide. *J Cardiovasc Pharmacol*. 1996;28:(6)856-61. [Rec#: 74]
117. Dollery C. Caffeine. In: Dollery C. (Ed) *Therapeutic Drugs*. New York, NY: Churchill Livingstone; 1991. pp. C3-C6. [Rec#: 75]
118. Dollery C. Ephedrine (Hydrochloride). In: Dollery C. (Ed) *Therapeutic Drugs*. New York, NY: Churchill Livingstone; 1991. p. E26-E29. [Rec#: 76]
119. Dollery C. Phenylpropanolamine (hydrochloride). In: Dollery C. (Ed) *Therapeutic Drugs*. New York, NY: Churchill Livingstone; 1991. pp. P91-P93. [Rec#: 77]
120. Dollery C. Pseudoephedrine hydrochloride. In: Dollery C. (Ed) *Therapeutic Drugs*. New York, NY: Churchill Livingstone; 1991. pp. P297-P299. [Rec#: 78]
121. Dougherty R. Pseudo-speed: look-alikes or peashooters. *NY State Journal of Medicine*. 1982;1:74-75. [Rec#: 524]
122. Doyle H, Kargin M. Herbal stimulant containing ephedrine has also caused psychosis. *BMJ*. 1996;313:(7059)756. [Rec#: 79]
123. Drew CD, Knight GT, Hughes DT, Bush M. Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. *Br J Clin Pharmacol*. 1978;6:(3)221-5. [Rec#: 80]
124. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: animal studies. *Am J Clin Nutr*. 1986;43:(3)388-94. [Rec#: 501]
125. Dulloo AG. Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. *Int J Obes Relat Metab Disord*. 1993;17:(Suppl 1)S35-40. [Rec#: 81]
126. Dulloo AG. Herbal stimulation of ephedrine and caffeine in treatment of obesity. *International Journal of Obesity*. 2002;26:590-2. [Rec#: 532]
127. Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. *Am J Clin Nutr*. 1999;70:(6)1040-5. [Rec#: 396]

Articles Excluded from Efficacy Analysis (continued)

128. Dulloo AG, Geissler CA, Horton T, et al. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. *Am J Clin Nutr.* 1989;49:(1)44-50. [Rec#: 374]
129. Dulloo AG, Miller DS. Thermogenic drugs for the treatment of obesity: sympathetic stimulants in animal models. *Br J Nutr.* 1984;52:(2)179-96. [Rec#: 385]
130. Dulloo AG, Miller DS. Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity. *Am J Clin Nutr.* 1987;45:(3)564-9. [Rec#: 386]
131. Dulloo AG, Miller DS. Ephedrine, caffeine and aspirin: "over-the-counter" drugs that interact to stimulate thermogenesis in the obese. *Nutrition.* 1989;5:(1)7-9. [Rec#: 82]
132. Dulloo AG, Seydoux J, Girardier L. Dietary and pharmacological effectiveness of thermogenic stimulation in obesity treatment. In: Oomura et al. (eds.) *Progress in Obesity Research*, 1990. London: John Libbey and Company, Lt.; 1991. pp. 135-144. [Rec#: 504]
133. Dulloo AG, Seydoux J, Girardier L. Peripheral mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose tissue. *Int J Obes.* 1991;15:(5)317-26. [Rec#: 364]
134. Dulloo AG, Seydoux J, Girardier L, et al. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. *Int J Obes Relat Metab Disord.* 2000;24:(2)252-8. [Rec#: 395]
135. Dulloo AG, Stock MJ. Ephedrine in the treatment of obesity. *Int J Obes Relat Metab Disord.* 1993;17:(Suppl 1)S1-2. [Rec#: 404]
136. Dunagan N, Greenleaf JE, Cisar CJ. Thermoregulatory effects of caffeine ingestion during submaximal exercise in men. *Aviat Space Environ Med.* 1998;69:(12)1178-81. [Rec#: 542]
137. Dvorak R, Starling RD, Calles-Escandon J, et al. Drug therapy for obesity in the elderly. *Drugs Aging.* 1997;11:(5)338-51. [Rec#: 84]
138. Dyck DJ. Dietary fat intake, supplements, and weight loss. *Can J Appl Physiol.* 2000;25:(6)495-523. [Rec#: 85]
139. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet.* 2000;356:(9237)1255-9. [Rec#: 480]
140. Edwards M, Russo L, Harwood-Nuss A. Cerebral infarction with a single oral dose of phenylpropanolamine. *Am J Emerg Med.* 1987;5:(2)163-4. [Rec#: 86]
141. Egger G, Cameron-Smith D, Stanton R. The effectiveness of popular, non-prescription weight loss supplements. *Med J Aust.* 1999;171:(11-12)604-8. [Rec#: 402]
142. Eldor J. Ephedrine in the initial treatment of haemorrhagic shock. *Med Hypotheses.* 1991;35:(3)250-2. [Rec#: 87]
143. Ellenhorn MJ, Barceloux DG. Over-the-counter products. In: Ellenhorn MJ, Barceloux DG. *Medical Toxicology: Diagnosis and Treatment of Human Poisoning*. New York, NY: Elsevier; 1988. pp. 501-559. [Rec#: 88]
144. Emanuelli A, Sacchetti G. An algorithm for the classification of untoward events in large scale clinical trials. *Agents Actions Suppl.* 1980;7:318-22. [Rec#: 321]
145. Emmanuel N, Jones C, Lydiard R. Use of herbal products and symptoms of bipolar disorder. *American Journal of Psychiatry.* 1998;155:1627. [Rec#: 519]
146. Emmanuel NP, Jones C, Lydiard RB. Use of herbal products and symptoms of bipolar disorder. *Am J Psychiatry.* 1998;155:(11)1627. [Rec#: 486]

Articles Excluded from Efficacy Analysis (continued)

147. Empey DW, Frosolono MF, Hughes DT, Perkins JG. Comparison of pseudoephedrine and triprolidine, alone and in combination in preventing nasal congestion in subjects with allergic rhinitis using nasal histamine challenge. *Br J Clin Pharmacol*. 1984;18:(1)86-9. [Rec#: 418]
148. Empey DW, Young GA, Letley E, John GC, Smith P, McDonnell KA, et al. Dose-response study of the nasal decongestant and cardiovascular effects of pseudoephedrine. *Br J Clin Pharmacol*. 1980;9:(4)351-8. [Rec#: 417]
149. Escobar JI, Karno M. Chronic hallucinosis from nasal drops. *JAMA*. 1982;247:(13)1859-60. [Rec#: 488]
150. Fairchild M D, Alles G A. The central locomotor stimulatory activity and acute toxicity of the ephedrine and norephedrine isomers in mice. *J Pharmacol Exp Ther*. 1967;158:(1)135-9. [Rec#: 89]
151. FDA. Center for Food Safety and Applied Nutrition. Assessment of Public Health Risks Associated with the Use of Ephedrine Alkaloid-Containing Dietary Supplements. 2000. [Rec#: 94]
152. FDA. Dietary supplements containing ephedra alkaloids. FDA docket no. 00N-1200. In: Rockville, MD: Food and Drug Administration. 2000. [Rec#: 440]
153. FDA. Spontaneous adverse events reports. available at URL: www.fda.gov/ohrms/dockets/ac/slides/3558sle/tsld003.htm.
154. Feller D R, Malspeis L. Biotransformation of D(-)-ephedrine and L(+)-ephedrine in the rabbit, in vivo and in vitro. *Drug Metab Dispos*. 1977;5:(1)37-46. [Rec#: 90]
155. Fillmore CM, Bartoli L, Bach R, Park Y. Nutrition and dietary supplements. *Phys Med Rehabil Clin N Am*. 1999;10:(3)673-703. [Rec#: 91]
156. Finer N. Present and future pharmacological approaches [obesity]. *British Medical Bulletin*. 1997;53:(2)409-432. [Rec#: 304]
157. Fisher CR, Veronneau SJ. Herbal preparations: a primer for the aeromedical physician. *Aviat Space Environ Med*. 2000;71:(1)45-60. [Rec#: 92]
158. Floch A, Lagente V, Freslon JL, Blanc M, Advenier C. [Bronchomotor effects of (-) ephedrine, (+/-) ephedrine and (+) pseudoephedrine in guinea pigs]. *Ann Pharm Fr*. 1985;43:(1)31-8. [Rec#: 369]
159. Flordal PA, Svensson J. Hemostatic effects of ephedrine. *Thromb Res*. 1992;68:(3)295-302. [Rec#: 93]
160. Flurer CL, Lin LA, Satzger RD, Wolnik KA. Determination of ephedrine compounds in nutritional supplements by cyclodextrin-modified capillary electrophoresis. *J Chromatogr B Biomed Appl* 1995 669:(1)133-9. [Rec#: 447]
161. Frick PA, Cohen LG, Rovers JP. Algorithms used in adverse drug event reports: a comparative study. *Ann Pharmacother*. 1997;31:(2)164-7. [Rec#: 330]
162. Fugh-Berman A. Clinical trials of Herbs. *Primary Care - Clinics Office Pract*. 1997;24:(4)889-903. [Rec#: 95]
163. Fugh-Berman A, Allina A. Ephedra for Weight Loss. *Alternative Therapies in Women's Health*. 2000;2:81-84. [Rec#: 312]
164. Garcia Ortiz JC, Terron M, Bellido J. Nonpigmenting fixed exanthema from ephedrine and pseudoephedrine. *Allergy*. 1997;52:(2)229-230. [Rec#: 522]
165. Garriott JC, Simmons LM, Poklis A, Mackell MA. Five cases of fatal overdose from caffeine-containing "look-alike" drugs. *J Anal Toxicol*. 1985;9:(3)141-3. [Rec#: 96]
166. Gaultieri J. Cardiomyopathy in a heavy ephedrine abuser. *J Toxicol Clin Toxicol*. 1996;34:581-582. [Rec#: 446]

Articles Excluded from Efficacy Analysis (continued)

167. Gilbert-Barness E, Drut RM. Association of sympathomimetic drugs with malformations. *Vet Human Toxicol.* 2000;42:(3)168-171. [Rec#: 98]
168. Gilbert EF, Matsuoka R, Bruyere H, Optiz JM. Teratogenic effect of Tedral (theophylline, ephedrine and phenobarbital) on cardiac development in chick embryos. *Circulation.* 1981;64:(Suppl 4)233(Abstract). [Rec#: 99]
169. Gill ND, Shield A, Blazeovich AJ, Zhou S, Weatherby RP. Muscular and cardiorespiratory effects of pseudoephedrine in human athletes. *Br J Clin Pharmacol.* 2000;50:(3)205-13. [Rec#: 100]
170. Gillies H, Derman WE, Noakes TD, Smith P, Evans A, Gabriels G. Pseudoephedrine is without ergogenic effects during prolonged exercise. *J Appl Physiol.* 1996;81:(6)2611-7. [Rec#: 101]
171. Glennon RA, Young R. (+)Amphetamine-stimulus generalization to an herbal ephedrine product. *Pharmacol Biochem Behav.* 2000;65:(4)655-8. [Rec#: 363]
172. Glick R, Hoying J, Cerullo L, Perlman S. Phenylpropanolamine: an over-the-counter drug causing central nervous system vasculitis and intracerebral hemorrhage. Case report and review. *Neurosurgery.* 1987;20:(6)969-74. [Rec#: 102]
173. Glidden RS, DiBona FJ. Urinary retention associated with ephedrine. *J Pediatr.* 1977;90:(6)1013-4. [Rec#: 103]
174. Goldberg LI, deV Cotton M, Darby TD, Howell EV. Comparative heart contractile force effects of equipressor doses of several sympathomimetic amines. *J Pharmacol Exp Ther.* 1953;108:177. [Rec#: 526]
175. Goldfrank LR, Hoffman RS. The cardiovascular effects of cocaine. *Ann Emerg Med.* 1991;20:(2)165-75. [Rec#: 104]
176. Gordiecheva NV, Shashkov VS, Kaplan EY, Lakota NG, Bliznets NI, Mikheeva LN, et al. Effectiveness of drugs on physical exercises. *Kosm Ciol Aviakosm Med.* 1975;9:(5)6-. [Rec#: 346]
177. Graham TE, Spriet LL. Performance and metabolic responses to a high caffeine dose during prolonged exercise. *J Appl Physiol.* 1991;71:(6)2292-8. [Rec#: 539]
178. Greening GK. The effect of an antihistamine-pseudoephedrine drug on the blood pressure of moderate hypertensives. *Curr Ther Res Clin Exp.* 1969;11:(5)252-5. [Rec#: 427]
179. Greenway F. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. *Obesity Reviews.* 2001;2:199-211. [Rec#: 314]
180. Greenway F, Herber D, Raum W, Herber D, Morales S. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. *Obes Res.* 1999;7:(4)370-8. [Rec#: 105]
181. Greenway FL. Clinical studies with phenylpropanolamine: a meta-analysis. *Am J Clin Nutr.* 1992;55:(1 Suppl)203S-205S. [Rec#: 307]
182. Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. *Obes Res.* 1999;7:(6)523-31. [Rec#: 398]
183. Griffith JD. Structure-activity relationships of several amphetamine drugs in man. In: Ellinwood EH Jr., Kilbey MM. (Eds) *Cocaine and other stimulants.* New York, NY: Plenum Press; 1977. pp. 705-15. [Rec#: 107]
184. Gruber AJ, Pope HG Jr. Ephedrine abuse among 36 female weightlifters. *Am J Addict.* 1998;7:(4)256-61. [Rec#: 108]

Articles Excluded from Efficacy Analysis (continued)

185. Grunberg E, Randall LO, Schnitzer RJ. The chemotherapeutic and pharmacological properties of the l-ephedrine salt of penicillin G (Tersavin). *J Pharmacol Exper Therapeut.* 1949;95:336-346. [Rec#: 109]
186. Gualtieri J, Harris C. Dilated cardiomyopathy in a heavy ephedrine abuser. *J Toxicol (Clin Toxicol).* 1996;34:(5)581-582(Abstract). [Rec#: 110]
187. Gurley BJ, Gardner SF, White LM, Wang P. Ephedrine pharmacokinetics after the ingestion of commercially available herbal preparations of ephedra sinica (Ma-huang). *Pharmaceut Res.* 1997;14:(11 Suppl)S519(Abstract). [Rec#: 111]
188. Gurley BJ, Gardner SF, White LM, Wang P. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). *Therapeut Drug Monit.* 1998;20:(4)439-445. [Rec#: 112]
189. Gurley BJ, Wang P, Gardner SF. Ephedrine alkaloid content of five commercially available herbal products containing ephedra sinica (Ma huang). *Pharmaceut Res.* 1997;14:(11 Suppl 1)S582-S582(Abstract). [Rec#: 113]
190. Gurley BJ, Wang P, Gardner SF. Ephedrine-type alkaloid content of nutritional supplements containing Ephedra sinica (Ma huang) as determined by high performance liquid chromatography. *J Pharmaceut Sci.* 1998;87:(12)1547-1553. [Rec#: 114]
191. Gurley DJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. *Am J Healthy Syst Pharm.* 2000;57. [Rec#: 115]
192. Haffner SM, Knapp JA, Stern MP, Hazuda HP, Rosenthal M, Franco LJ. Coffee consumption, diet, and lipids. *Am J Epidemiol.* 1985;122:(1)1-12. [Rec#: 381]
193. Hall RC, Beresford TP, Stickney SK, Nasdahl CS, Coleman JH. Psychiatric reactions produced by respiratory drugs. *Psychosomatics.* 1985;26:(7)605-8, 615-6. [Rec#: 489]
194. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. *N Engl J Med.* 2000;343:(25)1833-8. [Rec#: 116]
195. Han LK, Takaku T, Li J, Kimura Y, Okuda H. Anti-obesity action of oolong tea. *Int J Obes Relat Metab Disord.* 1999;23:(1)98-105. [Rec#: 393]
196. Hanzlick R. National Association of Medical Examiners Pediatric Toxicology (PedTox) Registry Report 3. Case submission summary and data for acetaminophen, benzene, carboxyhemoglobin, dextromethorphan, ethanol, phenobarbital, and pseudoephedrine. *Am J Forensic Med Pathol.* 1995;16:(4)270-7. [Rec#: 449]
197. Haseman JK. Patterns of tumor incidence in two-year cancer bioassay feeding studies in Fischer 344 rats. *Fundam Appl Toxicol.* 1983;3:(1)1-9. [Rec#: 117]
198. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. *Clin Pharmacol Ther.* 1996;60:(6)601-7. [Rec#: 118]
199. Herridge CF, Brook MF. Ephedrine psychosis. *Br Med J.* 1968;2:(598)160. [Rec#: 120]
200. Hirabayashi Y, Saitoh K, Fukuda H, Mitsuhata H, Shimizu R. Coronary artery spasm after ephedrine in a patient with high spinal anesthesia. *Anesthesiology.* 1996;84:(1)221-4. [Rec#: 121]
201. Hirsch MS, Walter RM, Hasterlik RJ. Subarachnoid hemorrhage following ephedrine and MAO inhibitor. *JAMA.* 1965;194:(11)1259. [Rec#: 485]

Articles Excluded from Efficacy Analysis (continued)

202. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptors antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A. (Eds) Goodman and Gillman's The Pharmacological Basis of Therapeutics. New York, NY, Toronto, ON: McGraw Hill; 1996. pp. 199-248. [Rec#: 122]
203. Horn J, Anderson K. Who in America is trying to lose weight? *Ann Intern Med.* 1993;119:672-676. [Rec#: 467]
204. Howard HJ, Lee TP. The effect of instillations of ephedrine solution upon the eye. *Proc Soc Exper Biol Med.* 1927;24:(7)700-702. [Rec#: 421]
205. Hu SY. Ephedra (ma-huang) in the new Chinese materia medica. *Economic Botany.* 1969;23:346-351. [Rec#: 505]
206. Hughes DT, Empey DW, Land M. Effects of pseudoephedrine in man. *J Clin Hosp Pharm.* 1983;8:(4)315-21. [Rec#: 128]
207. Hughes SC, Ward MG, Levinson G, Shnider SM, Wright RG, Gruenke LD, et al. Placental transfer of ephedrine does not affect neonatal outcome. *Anesthesiology.* 1985;63:(2)217-9. [Rec#: 129]
208. Hull KM, Maher TJ. L-tyrosine potentiates the anorexia induced by mixed-acting sympathomimetic drugs in hyperphagic rats. *J Pharmacol Exp Ther.* 1990;255:(2)403-9. [Rec#: 470]
209. Hull KM, Maher TJ. Effects of L-tyrosine on mixed-acting sympathomimetic-induced pressor actions. *Pharmacol Biochem Behav.* 1992;43:(4)1047-52. [Rec#: 469]
210. Hull KM, Sanderson WD, Maher TJ. Effect of phenylpropanolamine and related compounds on beta- adrenoceptor-induced activation of adenylyl cyclase. *Life Sci.* 1993;52:(15)1287-94. [Rec#: 468]
211. Hull KM, Zanzillari R, Maher TJ. Comparison between phenylpropanolamine and structurally related compounds on gastric transit in the rat. *Pharmacol Biochem Behav.* 1993;46:(2)411-4. [Rec#: 471]
212. Hurlbut JA, Carr JR, Singleton ER, Faul KC, Madson MR, Storey JM, et al. Solid-phase extraction cleanup and liquid chromatography with ultraviolet detection of ephedrine alkaloids in herbal products. *J AOAC Int.* 1998;81:(6)1121-7. [Rec#: 448]
213. Hutchins GM. Dietary supplements containing ephedra alkaloids. *N Engl J Med.* 2001;344:(14)1095-6; discussion 1096-7. [Rec#: 353]
214. Hutchinson TA, Leventhal JM, Kramer MS, Karch FE, Lipman AG, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity. *JAMA.* 1979;242:(7)633-8. [Rec#: 326]
215. Huxtable RJ. The myth of beneficent nature: the risks of herbal preparations. *Ann Intern Med.* 1992;117:(2)165-6. [Rec#: 130]
216. Hwang EJ, Kan EM, Yang KS, Park SB, Kim TH. Effects of ephedrae herba extract on cellular and humoral immune responses. *Korean J Pharmacog.* 1990;21:(3)256-. [Rec#: 350]
217. Insel PA. Beta-adrenergic receptors in pathophysiologic states and in clinical medicine. In: Perkins JP. (Ed) *The Beta-Adrenergic Receptors.* Clifton, NJ: Humana Press; 1991. pp. 295-343. [Rec#: 133]
218. Insel PA, Motusky HJ. Physiologic and pharmacologic regulation of adrenergic receptors. In: Insel PA. (Ed) *Adrenergic Receptors in Man.* New York, NY: Dekker; 1987. pp. 201-236. [Rec#: 134]

Articles Excluded from Efficacy Analysis (continued)

219. Ishigooka J, Yoshida Y, Murasaki M. Abuse of "BRON": a Japanese OTC cough suppressant solution containing methylephedrine, codeine, caffeine and chlorpheniramine. *Prog Neuropsychopharmacol Biol Psychiatry*. 1991;15:(4)513-21. [Rec#: 135]
220. Jacobs I, Bell DG. Acute physical performance effects after ingestion of ephedrine or ephedrine combined with caffeine. 2002. [Rec#: 530]
221. Jacobs KM, Hirsch KA. Psychiatric complications of Ma-huang. *Psychosomatics*. 2000;41:(1)58-62. [Rec#: 136]
222. James LP, Farrar HC, Komoroski EM, et al. Sympathomimetic drug use in adolescents presenting to a pediatric emergency department with chest pain. *Journal of Toxicology - Clinical Toxicology*. 1998;36:321-8. [Rec#: 517]
223. Jawad SS, Eccles R. Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. *Rhinology*. 1998;36:(2)73-6. [Rec#: 451]
224. Jequier E. Energy utilization in human obesity. *Ann N Y Acad Sci*. 1987;499:73-83. [Rec#: 400]
225. Jones JK. Approaches to evaluation causation of suspected drug reactions. In: Strom BL, Velo G. (Eds) *Drug Epidemiology and Post-Marketing Surveillance*. New York, NY: Plenum Press; 1992. pp. 103-113. [Rec#: 138]
226. Josefson D. Herbal stimulant causes US deaths. *BMJ*. 1996;312:(7044)1441. [Rec#: 309]
227. Jung RT, Shetty PS, James WP, Barrand MA, Callingham BA. Caffeine: its effect on catecholamines and metabolism in lean and obese humans. *Clin Sci (Colch)*. 1981;60:(5)527-35. [Rec#: 372]
228. Kalix P. The pharmacology of psychoactive alkaloids from ephedra and catha. *J Ethnopharmacol*. 1991;32:(1-3)201-8. [Rec#: 452]
229. Kalmar JM, Cafarelli E. Effects of caffeine on neuromuscular function. *J Appl Physiol*. 1999;87:(2)801-8. [Rec#: 540]
230. Kanai T, Nishikawa T, Satoh A, Kajita A. Cardiovascular teratogenicity of ephedrine in rats. *Senten Ijo (Cong Anom)*. 1986;26:(3)246. [Rec#: 141]
231. Kandil A, Shukrallah I, Hussein L, Azmy A. Biological and chemical evaluation of ephedrine. *J Drug Res (Egypt)*. 1983;14:(1/2)119-122. [Rec#: 349]
232. Kane FJ Jr., Florenzano R. Psychosis accompanying use of bronchodilator compound. *JAMA*. 1971;215:(13)2116. [Rec#: 490]
233. Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. *Pharmacotherapy*. 1993;13:(6 Pt 2)116S-128S; discussion 143S-146S. [Rec#: 142]
234. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. *Clin Pharmacol Ther*. 1977;21:(3)247-54. [Rec#: 322]
235. Karch SB, Green GS, Young S. Myocardial hypertrophy and coronary artery disease in male cocaine users. *J Forensic Sci*. 1995;40:(4)591-5. [Rec#: 143]
236. Karch SB. Synthetic stimulants <Fenfluramine, mescaline analogs>. In: Karch SB. *The Pathology of Drug Abuse*. Boca Raton, FL: CRC Press; 1993. pp. 199-218. [Rec#: 145]
237. Karch SB. Synthetic stimulants <Phenylpropanolamine>. In: Karch SB. *The Pathology of Drug Abuse*. Boca Raton, FL: CRC Press; 1993. pp. 165, 177-198. [Rec#: 146]

Articles Excluded from Efficacy Analysis (continued)

238. Karch SB. Ma huang and the ephedra alkaloids. In: Cupp MJ. (Ed) Toxicology and Clinical Pharmacology of Herbal Products. Totowa, NJ: Humana Press, Inc; 2000. pp. 11-30. [Rec#: 144]
239. Karch SB. Comments on "ma huang toxicity" letter by Dr. Theoharides. J Clin Psychopharmacol. 1999;19:(2)196-9. [Rec#: 454]
240. Kasahara Y, Hikino H, Tsurufuji S, Watanabe M, Ohuchi K. Anti-inflammatory actions of ephedrine in acute inflammations. Planta Med. 1985;51:(4)325-331. [Rec#: 351]
241. Keld DB, Bendsen AK. [Doping - a medical problem in Denmark?]. Ugeskr Laeger. 1998;160:(33)4749-53. [Rec#: 147]
242. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343:(25)1826-32. [Rec#: 148]
243. Kim TH, Yang KS, Hwang EZ, Park SB. Effect of ephedrae herba on the immune response in mice. Korean J Pharmacog. 1991;22:(3)183-91. [Rec#: 340]
244. Kimmel SE, Hutchins GM. *Commentary on the article: "Adverse cardiovascular events temporally associated with Mahuang, an herbal source of ephedrine," published in Mayo Clinic Proceedings, January 2002.* (Unpublished). [Rec#: 478]
245. Kitagawa H, Saito H. Differences in the effect of ephedrine isomers on blood pressure in rats. Jpn J Pharmacol. 1975;25:(4)473-5. [Rec#: 356]
246. Kizer KW. Intracranial hemorrhage associated with overdose of decongestant containing phenylpropanolamine. Am J Emerg Med. 1984;2:(2)180-1. [Rec#: 149]
247. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm. 1999;56:(2)125-38; quiz 139-41. [Rec#: 150]
248. Knight DC, Eden JA. Phytoestrogens: a short review. Maturitas. 1995;22:167-175. [Rec#: 311]
249. Kolata G. Appetite suppressants aid obese. The New York Times. July 5, 1992; Sect: 1:9(N), P12(L) (col. 4).
250. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979;242:(7)623-32. [Rec#: 327]
251. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. JAMA. 1994;272:205-211. [Rec#: 465]
252. Kuitunen T, Karkkainen S, Ylitalo P. Comparison of the acute physical and mental effects of ephedrine, fenfluramine, phentermine and prolintane. Methods Find Exp Clin Pharmacol. 1984;6:(5)265-70. [Rec#: 152]
253. Kustrak D, Ramic A. Ephedra species and the alkaloids of this plants. Farm Glas. 1994;50:(12)321-339. [Rec#: 153]
254. Laitinen LA, Empey DW, Bye C, Britton MG, McDonnell K, Hughes DT. A comparison of the bronchodilator action of pseudoephedrine and ephedrine in patients with reversible airway obstruction. Eur J Clin Pharmacol. 1982;23:(2)107-9. [Rec#: 154]
255. Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med. 1990;89:(2)195-208. [Rec#: 155]
256. Lake CR, Rosenberg DB, Gallant S, Zaloga G, Chernow B. Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther. 1990;47:(6)675-85. [Rec#: 156]

Articles Excluded from Efficacy Analysis (continued)

257. Lake CR, Tenglin R, Chernow B, Holloway HC. Psychomotor stimulant-induced mania in a genetically predisposed patient: a review of the literature and report of a case. *J Clin Psychopharmacol.* 1983;3:(2)97-100. [Rec#: 157]
258. Lake CQR. CNS stimulants and the look-alike drugs. *Psychiatr Clin North Am.* 1984;7:689-701. [Rec#: 525]
259. Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. *Clin Pharmacol Ther.* 1995;58:(6)692-8. [Rec#: 324]
260. Law MY, Pedersen GH, Hennen WJ, McCausland CW, Sidwell RW. Subacute toxicity study of ma-huang in mice. *Fundam Appl Toxicol.* 1996;30:(1-Prt. 2)111(Abtract). [Rec#: 158]
261. Lee EB. Teratogenicity of the extracts of crude drugs. *Saengyak Hakhoe Chi (Korean J Pharmacognosy).* 1982;13:116-121. [Rec#: 159]
262. Lee MK; Cheng BW; Che CT, et al. Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation. *Toxicol Sci* 2000 56:424-30. [Rec#: 513]
263. Lee MK, Cheng BW, Che CT, Hsieh DP. Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation. *Toxicol Sci.* 2000;56:(2)424-30. [Rec#: 160]
264. Lefebvre RA, Surmont F, Bouckaert J, Moerman E. Urinary excretion of ephedrine after nasal application in healthy volunteers. *J Pharm Pharmacol.* 1992;44:(8)672-5. [Rec#: 450]
265. Leung AY, Foster S. Ephedra. In: Leung AY, Foster S. *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics.* New York, NY: John Wiley; 1996. p. 227. [Rec#: 163]
266. Levine B, Jones R, Klette K, Smith M L, Kilbane E. An intoxication involving BRON and verapamil. *J Anal Toxicol.* 1993;17:(6)381-3. [Rec#: 164]
267. Levitsky DA, Strupp BJ. Direct and indirect thermogenic effects of anorectic drugs. *Adv Nutr Res.* 1985;7:187-201. [Rec#: 165]
268. Li Q, Li BH. [Comparison of central stimulating effects between ephedrine and apomorphine]. *Zhongguo Yao Li Xue Bao.* 1991;12:(5)468-71. [Rec#: 365]
269. Liljestrand SH. The action of pseudoephedrine. I. On the isolated uterus and bladder. *Chung-Kuo Sheng Li Hsueh Tsa Chih.* 1929;3:249-. [Rec#: 343]
270. Lin ET, Brater DC, Benet LZ. Gas-liquid chromatographic determination of pseudoephedrine and norpseudoephedrine in human plasma and urine. *J Chromatogr.* 1977;140:(3)273-9. [Rec#: 431]
271. Lindahl A, Sandstrom R, Ungell AL, Abrahamsson B, Knutson TW, Knutson L, et al. Jejunal permeability and hepatic extraction of fluvastatin in humans. *Clin Pharmacol Ther.* 1996;60:(5)493-503. [Rec#: 166]
272. Lindqvist A, Jalonon J, Laitinen LA, Seppala T, Stromberg C. The effects of midazolam and ephedrine on post-exercise autonomic chronotropic control of the heart in normal subjects. *Clin Auton Res.* 1996;6:(6)343-9. [Rec#: 167]
273. Lindsay BD. Are serious adverse cardiovascular events an unintended consequence of the Dietary Supplement Health and Education Act of 1994? *Mayo Clin Proc.* 2002;77:(1)7-9. [Rec#: 472]
274. Ling M, Piddlesden SJ, Morgan BP. A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement. *Clin Exp Immunol.* 1995;102:(3)582-8. [Rec#: 334]

Articles Excluded from Efficacy Analysis (continued)

275. Liu XX. [Pharmacologic action and clinical use of herbal Ephedrae]. *Zhong Xi Yi Jie He Za Zhi*. 1989;9:(4)255-6. [Rec#: 168]
276. Liu YM, Sheu SJ, Chiou SH, Chang HC, Chen YP. A comparative study on commercial samples of Ephedra Herba. *Planta Medica*. 1993;59:376-378. [Rec#: 506]
277. Loizou LA, Hamilton JG, Tsementzis SA. Intracranial haemorrhage in association with pseudoephedrine overdose. *J Neurol Neurosurg Psychiatry*. 1982;45:(5)471-2. [Rec#: 170]
278. Loosmore S, Armstrong D. Do-Do abuse. *Br J Psychiatry*. 1990;157:278-81. [Rec#: 171]
279. Lowell BB, Napolitano A, Usher P, Dulloo AG, Rosen BS, Spiegelman BM, et al. Reduced adiponin expression in murine obesity: effect of age and treatment with the sympathomimetic-thermogenic drug mixture ephedrine and caffeine. *Endocrinology*. 1990;126:(3)1514-20. [Rec#: 392]
280. LSRO. Alternative and Traditional Models for Safety Evaluation of Food Ingredients. Prepared for: Center for Food Safety and Applied Nutrition Food and Drug Administration Department of Health and Human Services, Washington DC 20204, under FDA Contract No. 223-92-2195, Task Order #9. Bethesda, MD: Life Sciences Research Office, American Society for Nutritional Sciences. 1998. [Rec#: 172]
281. Lustik SJ, Chhibber AK, van Vliet M, Pomerantz RM. Ephedrine-induced coronary artery vasospasm in a patient with prior cocaine use. *Anesth Analg*. 1997;84:(4)931-3. [Rec#: 174]
282. Lyon CC, Turney JH. Pseudoephedrine toxicity in renal failure. *Br J Clin Pract*. 1996;50:(7)396-7. [Rec#: 453]
283. Machii S. Pharmacological studies on the optical isomers of ephedrine and pseudoephedrine. *Nippon Yakurigaku Zasshi*. 1957;53:638-. [Rec#: 344]
284. Maertens P, Lum G, Williams J P, White J. Intracranial hemorrhage and cerebral angiopathic changes in a suicidal phenylpropanolamine poisoning. *South Med J*. 1987;80:(12)1584-6. [Rec#: 175]
285. Mahdihasan S. Ephedra the oldest medicinal plant with the history of an uninterrupted use. *Ancient Sci Life*. 1987;7:(2)105-9. [Rec#: 176]
286. Maitai CK. D-norpseudoephedrine as an anti-asthmatic: comparison with l-ephedrine, d-pseudoephedrine. *East Afr Med J*. 1975;52:(6)330-2. [Rec#: 425]
287. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. *Clin Pharmacol Ther*. 1971;12:(2)245-58. [Rec#: 178]
288. Martinez FV, Badas AJ, Goitia JFG, Aguirre I. Generalized dermatitis due to oral ephedrine. *Contact Dermatit*. 1993;29:(4)215-216. [Rec#: 179]
289. Marvola M. Effect of acetylated derivatives of some sympathomimetic amines on the acute toxicity, locomotor activity and barbiturate anaesthesia time in mice. *Acta Pharmacol Toxicol (Copenh)*. 1976;38:(5)474-89. [Rec#: 180]
290. Marvola M, Kivirinta R. Pharmacokinetics and locomotor activity increasing effect of ephedrine in mice. *Acta Pharmacol Toxicol (Copenh)*. 1978;43:(5)381-6. [Rec#: 181]
291. Massoudi M, Evans E, Miller DS. Thermogenic drugs for the treatment of obesity: screening using obese rats and mice. *Ann Nutr Metab*. 1983;27:(1)26-37. [Rec#: 384]
292. Massoudi M, Miller DS. Ephedrine, a thermogenic and potential slimming drug. *Proc Nutr Soc*. 1977;36:(3)135A. [Rec#: 182]

Articles Excluded from Efficacy Analysis (continued)

293. Matsuoka R, Gilbert EF, Bruyars H Jr., Optiz JM. An aborted human fetus with truncus arteriosus communis--possible teratogenic effect of Tedral. *Heart Vessels*. 1985;1:(3)176-8. [Rec#: 183]
294. Matthews G, Smolinske S, White S. Ephedrine-related stroke in a teenager. *J Toxicol (Clin Toxicol)*. 1997;35:(5)555(Abstract). [Rec#: 184]
295. May CS, Paterson JW, Spiro SG, Johnson AJ. Effect of intravenous injection of salbutamol in asthma. *Br J Clin Pharmacol*. 1975;2:(6)495-501. [Rec#: 185]
296. McCleave DJ, Phillips PJ, Vedig AE. Compartmental shift of potassium - a result of sympathomimetic overdose. *Aust N Z J Med*. 1978;8:(2)180-3. [Rec#: 482]
297. McKenna D. Ma huang. INPR. 2001. [Rec#: 508]
298. McLaurin JQ, Shipman WF, Rosedale R. Oral decongestants. A double blind comparison study of the effectiveness of four sympathomimetic drugs: Objective and subjective. *Laryngoscope*. 1961;71:54-67. [Rec#: 186]
299. McNamara SH. FDA Has Adequate Power and Authority to Protect the Public From Unsafe Dietary Supplements. *HERBALGRAM*. 1996;38:25-7. [Rec#: 187]
300. Mendez MF. Mania self-induced with cough syrup. *J Clin Psychiatry*. 1992;53:(5)173-4. [Rec#: 188]
301. Midha KK, Cooper JK, McGilveray IJ. Simple and specific electron-capture GLC assay for plasma and urine ephedrine concentrations following single doses. *J Pharm Sci*. 1979;68:(5)557-60. [Rec#: 189]
302. Miller DK, McMahon LR, Green TA, Nation JR, Wellman PJ. Repeated administration of ephedrine induces behavioral sensitization in rats. *Psychopharmacology (Berl)*. 1998;140:(1)52-6. [Rec#: 190]
303. Miller DS. A controlled trial using ephedrine in the treatment of obesity. *Int J Obes*. 1986;10:(2)159-60. [Rec#: 191]
304. Miller TG. A consideration of the clinical value of ephedrine. *American Journal of Medical Science*. 1925;170:157-181. [Rec#: 507]
305. Minimatsu S, Kobayashi Y, Kobayashi N, Juhii Y, Aburada M, Yamushita M. Acute ephedra herba and ephedrine poisoning in mice. *Chudoku Kenkyu*. 1991;4:143-149. [Rec#: 192]
306. Molenaar PC, Biewenga JE, Van Kempen GT, De Priester JA. Effect of ephedrine on muscle weakness in a model of myasthenia gravis in rats. *Neuropharmacology*. 1993;32:(4)373-6. [Rec#: 355]
307. Moolenaar M, Desmond PA, Mascord DJ, Starmer GA, Tattam B, Volkerts ER. The effects of ephedrine on the development of fatigue in a prolonged driving related task. *Hum Psychopharmacol Clin Exp*. 1999;14:(6)415-427. [Rec#: 345]
308. Mores N, Campia U, Navarra P, Cardillo C, Preziosi P. No cardiovascular effects of single-dose pseudoephedrine in patients with essential hypertension treated with beta-blockers. *Eur J Clin Pharmacol*. 1999;55:(4)251-4. [Rec#: 196]
309. Morgan JP. Phenylpropanolamine: A Critical Analysis of Reported Adverse Reactions and Overdosage. Fort Lee, NJ: Jack K. Burgess, Inc.; 1986. [Rec#: 198]
310. Morgan JP, Funderburk FR. Phenylpropanolamine and blood pressure: a review of prospective studies. *Am J Clin Nutr*. 1992;55:(1 Suppl)206S-210S. [Rec#: 463]
311. Morimoto I, Watanabe F, Osawa T, Okitsu T, Kada T. Mutagenicity screening of crude drugs with *Bacillus subtilis* rec-assay and *Salmonella*/microsome reversion assay. *Mutat Res*. 1982;97:(2)81-102. [Rec#: 199]

Articles Excluded from Efficacy Analysis (continued)

312. Morris HG, Rusnak SA, Selner JC, Barzens K, Barnes J. Comparative effects of ephedrine on adrenergic responsiveness in normal and asthmatic subjects. *J Allergy Clin Immunol*. 1978;61:(5)294-302. [Rec#: 200]
313. Mortimer EA Jr. Drug toxicity from breast milk? *Pediatrics*. 1977;60:(5)780-1. [Rec#: 201]
314. Mueller SM, Solow EB. Seizures associated with a new combination "pick-me-up" pill. *Ann Neurol*. 1982;11:(3)322. [Rec#: 487]
315. Nadeau SE. Intracerebral hemorrhage and vasculitis related to ephedrine abuse. *Ann Neurol*. 1984;15:(1)114-5. [Rec#: 484]
316. Nadeau SE. Intracerebral hemorrhage and vasculitis related to ephedrine abuse. *Ann Neurol*. 1984;15:(1)114-5. [Rec#: 455]
317. Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. *Am J Gastroenterol*. 1996;91:(7)1436-8. [Rec#: 202]
318. Nakahara Y, Kikura R. Hair analysis for drugs of abuse. XIX. Determination of ephedrine and its homologs in rat hair and human hair. *J Chromatogr B Biomed Sci Appl*. 1997;700:(1-2)83-91. [Rec#: 456]
319. Namba T, Kubo M, Kanai Y, Namba K, Nishimura H, Qazilbash NA. Pharmacognostical studies of Ephedra plants Part I - The comparative histological studies on Ephedra rhizomes from Pakistan and Afghanistan and Chinese crude drugs "Ma-Hung-Gen". *Planta Med*. 1976;29:(3)216-25. [Rec#: 203]
320. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther*. 1981;30:(2)239-45. [Rec#: 319]
321. National Academy of Sciences (NAS). National Academy of Sciences Model: Dietary Reference Intakes: A Risk Assessment Model for Establishing Upper Intake Levels for Nutrients. Washington DC: Institute of Medicine, National Academy Press (NAP). 1998. [Rec#: 205]
322. Nelson HS, Black JW, Branch LB, Pfuetze B, Spaulding H, Summers R, et al. Subsensitivity to epinephrine following the administration of epinephrine and ephedrine to normal individuals. *J Allergy Clin Immunol*. 1975;55:(5)299-309. [Rec#: 206]
323. Nesheim MC. What is the research base for the use of dietary supplements? *Public Health Nutr*. 1999;2:(1)35-8. [Rec#: 538]
324. Neve KA, Molinoff PB. Effects of chronic administration of agonists and antagonists on the density of beta-adrenergic receptors. *Am J Cardiol*. 1986;57:(12)17F-22F. [Rec#: 207]
325. Nightingale SL. From the Food and Drug Administration. *JAMA*. 1996;275:(20)1534. [Rec#: 495]
326. Nightingale SL. From the Food and Drug Administration. *JAMA*. 1996;276:(21)1710. [Rec#: 502]
327. NIOSH. Registry of Toxic Effects of Chemical Substances, Centers for Disease Control and Prevention. Ephedrine. 1997. [Rec#: 208]
328. Nishikawa T, Bruyere HJ Jr., Gilbert EF, Takagi Y. Potentiating effects of caffeine on the cardiovascular teratogenicity of ephedrine in chick embryos. *Toxicol Lett*. 1985;29:(1)65-8. [Rec#: 360]
329. Nishikawa THJ, Bruyere HJ Jr., Takagi Y, Gilbert EF, Uno H. Cardiovascular teratogenicity of ephedrine in chick embryos. *Toxicol Lett*. 1985;29:(1)59-63. [Rec#: 209]

Articles Excluded from Efficacy Analysis (continued)

330. Noble R. A controlled clinical trial of the cardiovascular and psychological effects of phenylpropanolamine and caffeine. *Drug Intell Clin Pharm.* 1988;22:(4)296-9. [Rec#: 382]
331. NTP. Toxicology and Carcinogenesis Studies of Ephedrine Sulfate (CAS No. 134-72-5) in F344/N Rats and B6C3F1 Mice (Feed Studies) National Toxicology Program (NTP), Research Triangle Park, NC, (NTP Technical Reports Series) No. 307. 1986. [Rec#: 211]
332. Nuotto E. Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man. *Eur J Clin Pharmacol.* 1983;24:(5)603-9. [Rec#: 212]
333. Nyland H. [Ephedrine, abuse and psychosis]. *Tidsskr Nor Laegeforen.* 1973;93:(27)2027-9. [Rec#: 213]
334. Oberman Z, Herzberg M, Jaskolka H, Harell A, Hoerer E, Laurian L. Changes in plasma cortisol, glucose and free fatty acids after caffeine ingestion in obese women. *Isr J Med Sci.* 1975;11:(1)33-6. [Rec#: 373]
335. Ogden JA. Congenital anomalies of the coronary arteries. *Am J Cardiol.* 1970;25:(4)474-9. [Rec#: 545]
336. Onuigbo M, Alikhan M. Over-the-counter sympathomimetics: a risk factor for cardiac arrhythmias in pregnancy. *South Med J.* 1998;91:(12)1153-5. [Rec#: 215]
337. Ooms TG, Khan SA, Means C. Suspected caffeine and ephedrine toxicosis resulting from ingestion of an herbal supplement containing guarana and ma huang in dogs: 47 cases (1997-1999). *J Am Vet Med Assoc.* 2001;218:(2)225-9. [Rec#: 216]
338. Oosterbaan R, Burns MJ. Myocardial infarction associated with phenylpropanolamine. *J Emerg Med.* 2000;18:(1)55-9. [Rec#: 217]
339. Pace S. Ma huang food supplement toxicity in two adolescents. *J Toxicol (Clin Toxicol).* 1996;34:(5)598(Abstract). [Rec#: 218]
340. Pantelis C, Hindler CG, Taylor JC. Use and abuse of khat (*Catha edulis*): a review of the distribution, pharmacology, side effects and a description of psychosis attributed to khat chewing. *Psychol Med.* 1989;19:(3)657-68. [Rec#: 219]
341. Pasquali R, Casimirri F. Clinical aspects of ephedrine in the treatment of obesity. *Int J Obes Relat Metab Disord.* 1993;17:(Suppl 1)S65-8. [Rec#: 221]
342. Pasquali R, Cesari MP, Besteghi L, Melchionda N, Balestra V. Thermogenic agents in the treatment of human obesity: preliminary results. *Int J Obes.* 1987;11:(Suppl 3)23-6. [Rec#: 390]
343. Patil PN, Tye A, Lapidus JB. A pharmacological study of the ephedrine isomers. *J Pharmacol Exper Therapeut.* 1965;148:(2)158-168. [Rec#: 422]
344. Pentel P. Toxicity of over-the-counter stimulants. *JAMA.* 1984;252:(14)1898-903. [Rec#: 368]
345. Pere JC, Begaud B, Haramburu F, Albin H. Computerized comparison of six adverse drug reaction assessment procedures. *Clin Pharmacol Ther.* 1986;40:(4)451-61. [Rec#: 329]
346. Perrota DM, Coody G, Culmo C. Adverse events associated with ephedrine-containing products: Texas, December 1993-September 1995. *JAMA.* 1996;276:(21)1711-1712. [Rec#: 224]
347. Peterson DI, Hardinge MG. The effect of various environmental factors on cocaine and ephedrine toxicity. *J Pharm Pharmacol.* 1967;19:(12)810-4. [Rec#: 225]
348. Pi-Sunyer XF. Medical hazards of obesity. *Ann Intern Med.* 1993;119:(7 pt 2)655-660. [Rec#: 464]

Articles Excluded from Efficacy Analysis (continued)

349. Pickup ME, May CS, Ssendagire R, Paterson JW. The pharmacokinetics of ephedrine after oral dosage in asthmatics receiving acute and chronic treatment. *Br J Clin Pharmacol.* 1976;3:(1)123-34. [Rec#: 226]
350. Pickupp ME, Paterson JW. The determination of ephedrine plasma levels by a gas chromatographic method. *J Pharm Pharmacol.* 1974;26:561-62. [Rec#: 432]
351. Pomerantz B, O'Rourke RA. The Stokes-Adams syndrome. *Am J Med.* 1969;46:(6)941-60. [Rec#: 227]
352. Porta M, Jick H, Habakangas JA. Follow-up study of pseudoephedrine users. *Ann Allergy.* 1986;57:(5)340-2. [Rec#: 426]
353. Powell T, et al. Dangers of Ma-huang. *Alternative Medicine Alert.* 1998;1:119. [Rec#: 313]
354. Powell T, Hsu FF, Turk J, Hruska K. Ma-huang strikes again: ephedrine nephrolithiasis. *Am J Kidney Dis.* 1998;32:(1)153-9. [Rec#: 228]
355. Puar HS. Acute memory loss and nominal aphasia caused by phenylpropanolamine. *South Med J.* 1984;77:(12)1604-5. [Rec#: 229]
356. Raadstroem M, Bengtsson J, Ederberg S, Bengtson A, Loswick AC, Bengtson JP. Effects of ephedrine on oxygen consumption and cardiac output. *Acta Anaesthesiol Scand.* 1995;39:(8)1084-87. [Rec#: 347]
357. Radstrom M, Bengtsson J, Ederberg S, Bengtsson A, Loswick AC, Bengtson JP. Effects of ephedrine on oxygen consumption and cardiac output. *Acta Anaesthesiol Scand.* 1995;39:(8)1084-7. [Rec#: 231]
358. Ramsey JJ, Colman RJ, Swick AG, Kemnitz JW. Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine. *Am J Clin Nutr.* 1998;68:(1)42-51. [Rec#: 232]
359. Rang HP, Dale MM. *Pharmacology.* New York, NY: Churchill Livingstone Inc.; 1995. [Rec#: 233]
360. Read BE, Feng CT. The alleged ephedrine action of two California species of ephedra. *Proc Soc Exp Biol Med.* 1927;24:819-21. [Rec#: 342]
361. Renwick AG. The use of an additional safety or uncertainty factor for nature of toxicity in the estimation of acceptable daily intake and tolerable daily intake values. *Regul Toxicol Pharmacol.* 1995;22:(3)250-61. [Rec#: 234]
362. Renwick AG, Lazarus NR. Human variability and noncancer risk assessment- An analysis of the default uncertainty factor. *Regul Toxicol Pharmacol.* 1998;27:(1 Pt 2)3-20. [Rec#: 235]
363. Robertson D, Frolich JC, Carr RK, Watson JT, Hollifield JW, Shand DG, et al. Effects of caffeine on plasma renin activity, catecholamines and blood pressure. *N Engl J Med.* 1978;298:(4)181-6. [Rec#: 236]
364. Rogers P, Eftimiades M, Aunapu G, Keller M, Jones R. Lethal but legal: an over-the-counter high takes the life of a college student. *People.* 1996;45:(20)105-109. [Rec#: 462]
365. Rosene JM, Rosene JA, Koczajowski DL, Paolone VJ. Decongestant effects on hemodynamics at rest, exercise, and recovery from exercise during--6 degrees of head down tilt. *Aviat Space Environ Med.* 1999;70:(1)15-21. [Rec#: 237]
366. Roth RP, Cantekin EI, Bluestone CD, Welch RM, Cho YW. Nasal decongestant activity of pseudoephedrine. *Ann Otol Rhinol Laryngol.* 1977;86:(2 pt. 1)235-42. [Rec#: 428]
367. Roxanas MG, Spalding J. Ephedrine abuse psychosis. *Med J Aust.* 1977;2:(19)639-40. [Rec#: 238]

Articles Excluded from Efficacy Analysis (continued)

368. Rutstein HR. Ingestion of pseudoephedrine. *Arch Otolaryngol.* 1963;77:145-47. [Rec#: 423]
369. Ryan DH. Medicating the obese patient. *Endocrinol Metab Clin North Am.* 1996;25:(4)989-1004. [Rec#: 239]
370. Sagara K, Oshima T, Misaki T. A simultaneous determination of norephedrine, pseudoephedrine, ephedrine and methylephedrine in Ephedrae Herba and oriental pharmaceutical preparations by ion-pair high-performance liquid chromatography. *Chem Pharm Bull (Tokyo).* 1983;31:(7)2359-65. [Rec#: 240]
371. Samenuk D, Link MS, Homoud MK, Contreras R, Theohardes TC, Wang PJ, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. *Mayo Clin Proc.* 2002;77:(1)12-6. [Rec#: 473]
372. Saunders A, Elliott P. Pseudoephedrine in the hypertensive patient. *Australian J Hospit Pharm.* 1987;17:(2)150-151. [Rec#: 424]
373. Sawynok J. Pharmacological rationale for the clinical use of caffeine. *Drugs.* 1995;49:(1)37-50. [Rec#: 383]
374. Schryver T. The buzz about ephedra and caffeine. *Dietitian's Edge.* 2001;March Apr:30-31, 33-34. [Rec#: 315]
375. Sever PS, Dring LG, Williams RT. The metabolism of (-)-ephedrine in man. *Eur J Clin Pharmacol.* 1975;9:(2-3)193-8. [Rec#: 242]
376. Sharma AN, Cinci PM, Hoffman RS. Ma huang-induced myocardial infarction with normal coronary arteries. *J Toxicol (Clin Toxicol).* 2000;38:(5)521(Abstract). [Rec#: 244]
377. Shenfield GM. Combination bronchodilator therapy. *Drugs.* 1982;24:(5)414-39. [Rec#: 245]
378. Sheu S-J. Identification by chemical analysis of the botanical sources of commercial samples of Chinese herbal drugs. Yao Wu Shih P'in Fen Hsi (*J Food Drug Anal.*) 1997;5:(4)285-294. [Rec#: 246]
379. Shu H, Jin B, Yang Z. The mechanism of inhibitory action of ephedrine on the twitch response of mouse vas deferens to field stimulation. *Sheng Li Hsueh Pao.* 1986;38:(6)583-88. [Rec#: 352]
380. Sieb JP, Engel AG. Ephedrine: effects on neuromuscular transmission. *Brain Res.* 1993;623:(1)167-71. [Rec#: 358]
381. Sinsheimer JE, Dring LG, Williams RT. Species differences in the metabolism of norephedrine in man, rabbit and rat. *Biochem J.* 1973;136:(3)763-71. [Rec#: 248]
382. Smith DA, Perry PJ. The efficacy of ergogenic agents in athletic competition. Part II: Other performance-enhancing agents. *Ann Pharmacother.* 1992;26:(5)653-9. [Rec#: 249]
383. Snook C, Otten M, Hassan M. Massive ephedrine overdose: Case report and toxicokinetic analysis. *Vet Hum Toxicol.* 1992;34:(4)335(Abstract). [Rec#: 250]
384. Sobal J, Marquart LF. Vitamin/mineral supplement use among athletes: a review of the literature. *Int J Sport Nutr.* 1994;4:(4)320-34. [Rec#: 537]
385. Sprague JE, Harrod AD, Teconchuk AL. Pharmacology and abuse potential of ephedrine. *Pharm Times.* 1998;64:72-80. [Rec#: 251]
386. Stoessl AJ, Young GB, Feasby TE. Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics. *Stroke.* 1985;16:734-6. [Rec#: 514]

Articles Excluded from Efficacy Analysis (continued)

387. Stromberg C, Vanakoski J, Olkkola KT, Lindqvist A, Seppala T, Laitinen LA. Exercise alters the pharmacokinetics of midazolam. *Clin Pharmacol Ther.* 1992;51:(5)527-32. [Rec#: 252]
388. Swain RA, Harsha DM, Baenziger J, Saywell RM. Do pseudoephedrine or phenylpropanolamine improve maximum oxygen uptake and time to exhaustion? *Clin J Sport Med.* 1997;7:(3)168-73. [Rec#: 253]
389. Tagliabue A, Terracina D, Cena H, Turconi G, Lanzola E, Montomoli C. Coffee induced thermogenesis and skin temperature. *Int J Obes Relat Metab Disord.* 1994;18:(8)537-41. [Rec#: 377]
390. Takaku T, Ming J, Okuda H, Maeda N. Isolation of insulin-like substances from ephedra sinica stapf. *Wakan Iyakugaku Zasshi.* 1997;14:(4)358-9. [Rec#: 332]
391. Takayasu T, Ohshima T, Ohtsuji M, Takayama N, Kondo T, Lin Z, et al. False identification of urinary ephedrine as methamphetamine by gas chromatography/mass spectrometry with a DB-17 column. *Nippon Hoigaku Zasshi.* 1997;51:(3)235-40. [Rec#: 459]
392. Tamada M, Endo K, Hikino H. Maokonine, hypertensive principle of Ephedra roots. *Planta Med.* 1978;34:(3)291-3. [Rec#: 336]
393. Tamada M, Endo K, Hikino H, Kabuto C. Structure of Ephedradine A, a hypotensive principle of ephedra roots. *Planta Med.* 1978;34:291. [Rec#: 341]
394. Tanaka M, Dohi S. [The effects of ephedrine and phenylephrine on arterial partial pressure of oxygen during one-lung ventilation]. *Masui.* 1994;43:(8)1124-9. [Rec#: 254]
395. Tashkin DP, Meth R, Simmons DH, Lee YE. Double-blind comparison of acute bronchial and cardiovascular effects of oral terbutaline and ephedrine. *Chest.* 1975;68:(2)155-61. [Rec#: 256]
396. Taylor DM, O'Toole KS, Auble TE, Ryan CM, Sherman DR. The psychometric and cardiac effects of pseudoephedrine in the hyperbaric environment. *Pharmacotherapy.* 2000;20:(9)1045-50. [Rec#: 257]
397. Tekol Y, Tercan E, Esmaglu A. Ephedrine enhances analgesic effect of morphine. *Acta Anaesthesiol Scand.* 1994;38:(4)396-7. [Rec#: 457]
398. Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. *J Clin Psychopharmacol.* 1997;17:(5)437-9. [Rec#: 258]
399. Tinsley JA, Watkins DD. Over-the-counter stimulants: abuse and addiction. *Mayo Clin Proc.* 1998;73:(10)977-82. [Rec#: 493]
400. Tinsley JA. The hazards of psychotropic herbs. *Minn Med.* 1999;82:(5)29-31. [Rec#: 259]
401. To LB, Sangster JF, Rampling D, Cammens I. Ephedrine-induced cardiomyopathy. *Med J Aust.* 1980;2:(1)35-6. [Rec#: 260]
402. Toubro S, Astrup A, Breum L, Quaade F. The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans. *Int J Obes Relat Metab Disord.* 1993;17:(Suppl 3)S73-7; discussion S82. [Rec#: 262]
403. Traub SJ, Hoyek W, Hoffman RS. Dietary supplements containing ephedra alkaloids. *New England Journal of Medicine.* 2001;344:1096. [Rec#: 516]
404. Turner JE, Cravey RH. A fatal ingestion of caffeine. *Clin Toxicol.* 1977;10:(3)341-4. [Rec#: 264]
405. Tyler VE. *The Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies.* New York, NY: Pharmaceutical Products Press (PPP); 1993. pp. 119-121. [Rec#: 265]

Articles Excluded from Efficacy Analysis (continued)

406. Ueng TH, Kang JJ, Wang HW, Cheng YW, Chiang LY. Suppression of microsomal cytochrome P450-dependent monooxygenases and mitochondrial oxidative phosphorylation by fullerene, a polyhydroxylated fullerene C60. *Toxicol Lett.* 1997;93:(1)29-37. [Rec#: 266]
407. Ueng T-H, Kang J-J, Wang H-W, Lin P-C. An overview of the toxicology of commonly used traditional Chinese medicine. *Yao Wu Shih P'in Fen Hsi (J Food Drug Anal).* 1997;5:(4)241-264. [Rec#: 267]
408. Unger DL. Blood pressure and pulse rate changes in hypertensive asthmatic patients: effects of an ephedrine compound. *Ann Allergy.* 1968;26:(12)637-8. [Rec#: 429]
409. United States General Accounting Office. Dietary Supplements: Uncertainties in Analyses Underlying FDA's Proposed Rule on Ephedrine Alkaloids. Washington, DC: United States General Accounting Office. 1999. [Rec#: 268]
410. Upton RA. Pharmacokinetic interactions between theophylline and other medication (Part I). *Clin Pharmacokinet.* 1991;20:(1)66-80. [Rec#: 269]
411. USDA. Dietary supplements containing ephedrine alkaloids; proposed rule. 21 CFR 111. Federal Register. 1997;62:(107)30677-724. [Rec#: 445]
412. Vahedi K, Domigo V, Amarenco P, Bousser M G. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. *J Neurol Neurosurg Psychiatry.* 2000;68:(1)112-3. [Rec#: 270]
413. Van Mieghem W, Stevens E, Cosemans J. Ephedrine-induced cardiopathy. *Br Med J.* 1978;1:(6116)816. [Rec#: 271]
414. Vanakoski J, Seppala T. Heat exposure and drugs. A review of the effects of hyperthermia on pharmacokinetics. *Clin Pharmacokinet.* 1998;34:(4)311-22. [Rec#: 273]
415. Vanakoski J, Stromberg C, Seppala T. Effects of a sauna on the pharmacokinetics and pharmacodynamics of midazolam and ephedrine in healthy young women. *Eur J Clin Pharmacol.* 1993;45:(4)377-81. [Rec#: 274]
416. Vansal SS, Feller DR. Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. *Biochem Pharmacol.* 1999;58:(5)807-10. [Rec#: 361]
417. Villas Martinez F, Badas AJ, Garmendia Goitia JF, Aguirre I. Generalized dermatitis due to oral ephedrine. *Contact Dermatitis.* 1993;29:(4)215-6. [Rec#: 503]
418. Wahl M, Grant C, Jespersen R. Acute psychosis from a dietary weight control supplement. *J Toxicol (Clin Toxicol).* 2000;38:(5)522-523.(Abstract). [Rec#: 275]
419. Walker RB, Fitz LD, Williams LM, Linton H Jr., Smith CC. The effect of ephedrine isomers and their oxazolidines on locomotor activity in rats. *Gen Pharmacol.* 1993;24:(3)669-73. [Rec#: 359]
420. Warot D, Berlin I, Aymard G, Acquaviva E, Legrand M, Labarthe B, et al. Comparative pharmacodynamics and pharmacokinetics of oral and intranasal ephedrine. *Fun & Clin Pharma.* 2000. Abstract 237-297. [Rec#: 277]
421. Warren MR, Werner HW. Acute toxicity of vasopressor amines: II. Comparative data. *J Pharmacol Exper Therapeut.* 1945;86:284-286. [Rec#: 278]
422. Warren MR, Werner HW. The central stimulant action of some vasopressor amines. *J Pharmacol Exper Therapeut.* 1945;85:119-121. [Rec#: 279]
423. Warren MR, Werner HW. Effect of temperature on the toxicity of some vasopressor amines. *Fed Proc (FASEB).* 1945;4:139(Abstract). [Rec#: 280]

Articles Excluded from Efficacy Analysis (continued)

424. Webb AA, Shipton EA. Re-evaluation of i.m. ephedrine as prophylaxis against hypotension associated with spinal anaesthesia for Caesarean section. *Can J Anaesth*. 1998;45:(4)367-9. [Rec#: 458]
425. Weesner KM, Denison M, Roberts RJ. Cardiac arrhythmias in an adolescent following ingestion of an over-the-counter stimulant. *Clin Pediatr (Phila)* 1982 21:(11)700-1. [Rec#: 281]
426. Weinberger M, Bronsky E, Bensch GW, Bock GN, Yecies JJ. Interaction of ephedrine and theophylline. *Clin Pharmacol Ther*. 1975;17:(5)585-92. [Rec#: 282]
427. Weiner I, Tilkian AG, Palazzolo M. Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion. *Cathet Cardiovasc Diagn*. 1990;20:(1)51-3. [Rec#: 437]
428. Welling PG, Lee KP, Patel JA, Walker JE, Wagner JG. Urinary excretion of ephedrine in man without pH control following oral administration of three commercial ephedrine sulfate preparations. *J Pharm Sci*. 1971;60:(11)1629-34. [Rec#: 283]
429. Wellman PJ, Miller DK, Livermore CL, Green TA, McMahon LR, Nation JR. Effects of (-)-ephedrine on locomotion, feeding, and nucleus accumbens dopamine in rats. *Psychopharmacology (Berl)*. 1998;135:(2)133-40. [Rec#: 354]
430. White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M. Pharmacokinetics and cardiovascular effects of ma-huang (*Ephedra sinica*) in normotensive adults. *J Clin Pharmacol*. 1997;37:(2)116-22. [Rec#: 284]
431. Whitehouse AM, Duncan JM. Ephedrine psychosis rediscovered. *Br J Psychiatry*. 1987;150:258-61. [Rec#: 285]
432. WHO. Principles for the Safety Assessment of Food Additives and Contaminants in Food. World Health Organization (WHO), International Programme on Chemical Safety (IPCS), Geneva, Switz. Environmental Health Criteria No. 70. 1987. [Rec#: 286]
433. Wiener ITAPM. Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion. *Catheterization & Cardiovascular Diagnosis*. 1990;20:51-3. [Rec#: 518]
434. Wilkinson GR, Beckett AH. Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output. *J Pharmacol Exp Ther*. 1968;162:(1)139-47. [Rec#: 287]
435. Wilkinson GR, Beckett AH. Absorption, metabolism, and excretion of the ephedrines in man. II. Pharmacokinetics. *J Pharm Sci*. 1968;57:(11)1933-8. [Rec#: 288]
436. Williams R, Caldwell J, Dring L. Comparative metabolism of some amphetamines in various species. In: Usdin E, Snyder S. (Eds) *Frontiers in Catecholamine Research*. New York, NY: Pergamon Press; 1973. pp. 927-932. [Rec#: 289]
437. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. *Am J Epidemiol*. 1995;141:(12)1128-41. [Rec#: 544]
438. Wilson AF, Novey HS, Cloninger P, Davis J, White D. Cardiopulmonary effects of long-term bronchodilator administration. *J Allergy Clin Immunol*. 1976;58:(1 PT. 2)204-12. [Rec#: 290]
439. Wolf HH, Schuster MA, Lanciault G. 'Aggregation' phenomenon and some ephedrine isomers. *J Pharmaceut Sci*. 1964;53:987-988. [Rec#: 291]

Articles Excluded from Efficacy Analysis (continued)

440. Wood KA. Nasal decongestant and psychiatric disturbance. *Br J Psychiatry*. 1994;164:(4)566-7. [Rec#: 492]
441. Wooten MR, Khangure MS, Murphy MJ. Intracerebral hemorrhage and vasculitis related to ephedrine abuse. *Ann Neurol*. 1983;13:(3)337-40. [Rec#: 438]
442. Xue-Jun Y, De-xiang L, Hechuan W, Yu Z. A study on the mutagenicity of 102 raw pharmaceuticals used in Chinese traditional medicine. *Mutat Res*. 1991;260:(1)73-82. [Rec#: 292]
443. Yacobi A, Stoll RG, Chao GC, Carter JE, Baaske DM, Kamath BL, et al. Evaluation of sustained-action chlorpheniramine-pseudoephedrine dosage form in humans. *J Pharm Sci*. 1980;69:(9)1077-81. [Rec#: 430]
444. Yale Hemorrhagic Stroke Project Final Study Report. The safety of phenylpropanolamine hydrochloride (PPA) used in OTC weight control and nasal decongestant drug products. 2000. [Rec#: 293]
445. Yates KM, O'Connor A, Horsley CA. "Herbal Ecstasy": a case series of adverse reactions. *N Z Med J*. 2000;113:(1114)315-7. [Rec#: 294]
446. Yen TT, McKee MM, Bemis KG. Ephedrine reduces weight of viable yellow obese mice (Avy/a). *Life Sci*. 1981;28:(2)119-28. [Rec#: 295]
447. Yin P. Ephedrine-induced intracerebral hemorrhage and central nervous system vasculitis. *Stroke*. 1990;21:1641. [Rec#: 515]
448. Yin PA. Ephedrine-induced intracerebral hemorrhage and central nervous system vasculitis. *Stroke*. 1990;21:(11)1641. [Rec#: 483]
449. Yoovathaworn KC, Sriwatanakul K, Thithapandha A. Influence of caffeine on aspirin pharmacokinetics. *Eur J Drug Metab Pharmacokinet*. 1986;11:(1)71-6. [Rec#: 296]
450. Yoshida T, Sakane N, Umekawa T, Kondo M. Relationship between basal metabolic rate, thermogenic response to caffeine, and body weight loss following combined low calorie and exercise treatment in obese women. *Int J Obes Relat Metab Disord*. 1994;18:(5)345-50. [Rec#: 379]
451. Yoshida T, Sakane N, Wakabayashi Y, Umekawa T, Kondo M. Thermogenic, anti-obesity effects of bofu-tsusho-san in MSG-obese mice. *Int J Obes Relat Metab Disord*. 1995;19:(10)717-22. [Rec#: 394]
452. Young R, Gabryszuk M, Glennon RA. (-)Ephedrine and caffeine mutually potentiate one another's amphetamine- like stimulus effects. *Pharmacol Biochem Behav*. 1998;61:(2)169-73. [Rec#: 357]
453. Young R, Glennon RA. Discriminative stimulus properties of (-)ephedrine. *Pharmacol Biochem Behav*. 1998;60:(3)771-5. [Rec#: 494]
454. Yuan D, Komatsu K, Cui Z, Kano Y. Pharmacological properties of traditional medicines. XXV. Effects of ephedrine, amygdalin, glycyrrhizin, gypsum and their combinations on body temperature and body fluid. *Biol Pharm Bull*. 1999;22:(2)165-71. [Rec#: 362]
455. Zaacks SM, Klein L, Tan CD, Rodriguez ER, Leikin JB. Hypersensitivity myocarditis associated with ephedra use. *J Toxicol Clin Toxicol*. 1999;37:(4)485-9. [Rec#: 297]
456. Zahn KA, Li RL, Purssell RA. Cardiovascular toxicity after ingestion of "herbal ecstasy." *J Emerg Med*. 1999;17:(2)289-91. [Rec#: 298]
457. Zeisel SH. Is there a metabolic basis for dietary supplementation? *Am J Clin Nutr*. 2000;72:(2 Suppl)507S-11S. [Rec#: 299]

Articles Excluded from Efficacy Analysis (continued)

458. Zgourides GD, Warren R, Englert ME. Ephedrine-induced thermogenesis as an adjunct to cognitive restructuring and covert conditioning: a proposal for treatment of obese individuals. *Percept Mot Skills*. 1989;69:(2)563-72. [Rec#: 401]
459. Zhang J, Tian Z, Lou ZC. Simultaneous determination of six alkaloids in Ephedrae herba by high performance liquid chromatography. *Planta Med*. 1988;54:(1)69-71. [Rec#: 300]
460. Zhang JS, Tian Z, Lou ZC. Quality evaluation of twelve species of Chinese Ephedra (ma-huang). *Chung Kuo Yao Li Hsueh Pao (Acta Pharmacologica Sinica)*. 1993;22:419-425. [Rec#: 301]

Case Report and Case Series Articles Identified

ID#: 17	Backer R, Tautman D, Lowry S, Harvey CM, Poklis A. Fatal ephedrine intoxication. <i>J Forensic Sci.</i> 1997;42(1):157-9.	ID#: 184	Matthews G, Smolinske S, White S. Ephedrine-related stroke in a teenager. <i>J Toxicol (Clin Toxicol).</i> 1997;35(5):555(Abstract).
ID#: 44	Bruno A, Nolte KB, Chapin J. Stroke associated with ephedrine use. <i>Neurology.</i> 1993;43(7):1313-6.	ID#: 218	Pace S. Ma huang food supplement toxicity in two adolescents. <i>J Toxicol (Clin Toxicol).</i> 1996;34(5):598(Abstract).
ID#: 48	Capwell RR. Ephedrine-induced mania from an herbal diet supplement. <i>Am J Psychiatry.</i> 1995;152(4):647.	ID#: 224	Perrota DM, Coody G, Culmo C. Adverse events associated with ephedrine-containing products: Texas, December 1993-September 1995. <i>JAMA.</i> 1996;276(21):1711-1712.
ID#: 64	Cockings JG, Brown M. Ephedrine abuse causing acute myocardial infarction. <i>Med J Aust.</i> 1997;167(4):199-200.	ID#: 238	Roxanas MG, Spalding J. Ephedrine abuse psychosis. <i>Med J Aust.</i> 1977;2(19):639-40.
ID#: 69	Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. <i>J Accid Emerg Med.</i> 1995;12(1):49-51.	ID#: 244	Sharma AN, Cinci PM, Hoffman RS. Ma huang-induced myocardial infarction with normal coronary arteries. <i>J Toxicol (Clin Toxicol).</i> 2000;38(5):521(Abstract).
ID#: 79	Doyle H, Kargin M. Herbal stimulant containing ephedrine has also caused psychosis. <i>BMJ.</i> 1996;313(7059):756.	ID#: 250	Snook C, Otten M, Hassan M. Massive ephedrine overdose: Case report and toxicokinetic analysis. <i>Vet Hum Toxicol.</i> 1992;34(4):335(Abstract).
ID#: 96	Garriott JC, Simmons LM, Poklis A, Mackell MA. Five cases of fatal overdose from caffeine-containing "look-alike" drugs. <i>J Anal Toxicol.</i> 1985;9(3):141-3.	ID#: 258	Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. <i>J Clin Psychopharmacol.</i> 1997;17(5):437-9.
ID#: 110	Gualtieri J, Harris C. Dilated cardiomyopathy in a heavy ephedrine abuser. <i>J Toxicol (Clin Toxicol).</i> 1996;34(5):581-582.(Abstract).	ID#: 260	To LB, Sangster JF, Rampling D, Cammens I. Ephedrine-induced cardiomyopathy. <i>Med J Aust.</i> 1980;2(1):35-6.
ID#: 120	Herridge CF, Brook MF. Ephedrine psychosis. <i>Br Med J.</i> 1968;2(598):160.	ID#: 271	Van Mieghem W, Stevens E, Cosemans J. Ephedrine-induced cardiopathy. <i>Br Med J.</i> 1978;1(6116):816.
ID#: 136	Jacobs KM, Hirsch KA. Psychiatric complications of Ma-huang. <i>Psychosomatics.</i> 2000;41(1):58-62.	ID#: 281	Weesner KM, Denison M, Roberts RJ. Cardiac arrhythmias in an adolescent following ingestion of an over-the-counter stimulant. <i>Clin Pediatr (Phila).</i> 1982;21(11):700-1.
ID#: 157	Lake CR, Tenglin R, Chernow B, Holloway HC. Psychomotor stimulant-induced mania in a genetically predisposed patient: a review of the literature and report of a case. <i>J Clin Psychopharmacol.</i> 1983;3(2):97-100.	ID#: 285	Whitehouse AM, Duncan JM. Ephedrine psychosis rediscovered. <i>Br J Psychiatry.</i> 1987;150:258-61.
ID#: 174	Lustik SJ, Chhibber AK, van Vliet M, Pomerantz RM. Ephedrine-induced coronary artery vasospasm in a patient with prior cocaine use. <i>Anesth Analg.</i> 1997;84(4):931-3.	ID#: 297	Zaacks SM, Klein L, Tan CD, Rodriguez ER, Leikin JB. Hypersensitivity myocarditis associated with ephedra use. <i>J Toxicol Clin Toxicol.</i> 1999;37(4):485-9.

Case Report and Case Series Articles Identified (continued)

- ID#: 438 Wooten MR, Khangure MS, Murphy MJ. Intracerebral hemorrhage and vasculitis related to ephedrine abuse. *Ann Neurol*. 1983;13(3):337-40.
- ID#: 462 Rogers P, Eftimiades M, Aunapu G, Keller M, Jones R. Lethal but legal: an over-the-counter high takes the life of a college student. *People*. 1996;45(20):105-109.
- ID#: 485 Hirsch MS, Walter RM, Hasterlik RJ. Subarachnoid hemorrhage following ephedrine and MAO inhibitor. *JAMA*. 1965;194(11):1259.
- ID#: 488 Escobar JI, Karno M. Chronic hallucinosis from nasal drops. *JAMA*. 1982;247(13):1859-60.
- ID#: 490 Kane FJ Jr., Florenzano R. Psychosis accompanying use of bronchodilator compound. *JAMA*. 1971;215(13):2116.
- ID#: 493 Tinsley JA, Watkins DD. Over-the-counter stimulants: abuse and addiction. *Mayo Clin Proc*. 1998;73(10):977-82.
- ID#: 514 Stoessl A, Young G, Feasby T. Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics. *Stroke*. 1985;16:734-6.
- ID#: 515 Yin P. Ephedrine-induced intracerebral hemorrhage and central nervous system vasculitis. *Stroke*. 1990;21:1641.
- ID#: 516 Traub S, Hoyek W, Hoffman R. Dietary supplements containing ephedra alkaloids. *New England Journal of Medicine*. 2001;344:1096.
- ID#: 519 Emmanuel N, Jones C, Lydiard R. Use of herbal products and symptoms of bipolar disorder. *American Journal of Psychiatry*. 1998;155:1627.
- ID#: 552 Kaberi-Otarod J, Conetta R, Kundo KK, Farkash A. Ischemic stroke in a user of Thermadrene: A case study in alternative medicine. *Clin Pharmacol Ther*. 2002;72:343-6.